var title_f24_6_24672="Thyroid ultrasound showing thyroid anatomy";
var content_f24_6_24672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid ultrasound showing thyroid anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 304px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEwAS0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1Gf4HeFTFEbGztFKnJ8yAMH9vas69+EXgTTbh/wC1ZdJs/tC5SOXZGVx12bm5FTaV8W/tWrjz9AeIA+WZY5iwPvjFecT+MfD2src6vquhwa9quoag9oLaWcq1tGGwgRSOBjkmgD1SX4f/AAx0i1hhvodHjF0v7mWZowWHqCePxq7pfwk8GppE8VrYWV1BdfPHO0KSEDttYDkfSvDPBd9o+r+PJIbqHS7jRIZBZ2dpeO7TRxLknyx0JJz1r6c0jVIjaWcGm6e0NoQIod2EVFA4GPw6UAcPc/BHwmb63kNhAYMbJEEYGeOoxVWy+AXhq1vJJywkUE+SjQJhf97+9Xq8t2sDH7SyxpkKCQfmJ9PWuX1ix8QazO/9mavbQ2aMMqYGUt6jNAHIH4JaDcRSONPgt7vOG3Ivlt/tAAcfSsp/hmlrqAt9R0GG9RY8RT2tqmwDtu46j3rvVl1jQtY2SX1rPaPFuZJXOIiOwya1pr3UNV01o4YVtzONsciT/NjuRjp+dAHn2mfBDTUmW4vo7N5Hb5wkIwF9uMZrWt/gt4a80tfIbpB9xfKRNv4gc1uy/wDCSzWDppl7Z2txD8ixXa+YWAHUnrz615prnxB8daJaSPcxWdwythnjjBVPy60AehWHwt8M2lteW/8AZtpLHcAKGkt0LoPZsdaqRfB7wvGMC2yAwZfkXI/TmuKT4ueIp9Gtzb2ERumJLzNCdpHsM1vX/wATdHttBF5capdTaiVAkskiGB68Y6e+aAOv/wCFf+E7a4S9/smyhmiXb5uxRx6ntUsHgnR4Lq5eGxtUinjCtiFc7s9elct4d+JuheINOGm6dYzy3Uq7I7Vl+V8+p7VoR6lqPh7RjBan+0L5SS6Mx8uIegJ54oAvXHw38PXNwXubcPyHWMKihCO4wK09Q8IaReWksJtIIy44dYUyv04qnoHiwXOm2zXVjftdEEP5cJdc/wC90qjefEzSLXUFtZYLtJd4Qo6bWBzjp6UATaP8ONC05vMkiNxcEEeY4C8fQCrE/gXRIIM6eg01sgyTRYy49CTUniHx1omi2jTSXcczjGI425/H0qhofjC38VTmGz0iSbau5nkddgH+fagDRtPBuix3Qvdrzzlcec7gkj8BirB8N6HeWK2wtoZbVWJZFIIY/wC0RWHrvgqzkc3J1CXT7RlPnwtLhAO+KqeH/B9hb6Zjwp4hnS5U8TLIHUj0ZO9AG/rXhbRbuyg09zHZRsQuISqPIB/Dk8mqumfD3wxpcwMNmDcOpCtI+W+oH/1q43xfpr3GuJb654oEKWkQdpmjxnPbaOhqRPCyWaQ62ni6S6tDjy9zFTjuFbcT+GKAPQn8M6O+lrZ3ECTW6MSGkIyD35FYEXgLwtYSh5ZnNqGyLaa4Hkhj7f8A16yr/wAB219uuY/FUq2cvzZchsZ9DuH8qisvhtZbQItbuL62DYk2YbacexNAHdad4d0OEtPY2dsSzbllQBipH909qsnS7KSWWSVjKz/KSzA4P+NcTb32heE5o1j8Q7rd+BbAFsv6kjp9K1bHx14cud730sNlInGZjgEezUAdJZaPZ2czSxRlpSch3O4j6elJq2kWeptE96pYQ5I5wOf/ANVUNLGnRW07Qays0F2d8b/aFJUf7LZrM/4Q29/tJrxPEuosp+5HL+8Cg9R15oA2oPDuiF4547K3lkTAWU/MRjuD61qN5MC73KIFGN7noPqawdP0FdIxcyapOIo8yS5IVGx3PoKpvrfh3xRZyKt+whjJD4bZux/OgCvr+leEIPtN9fXcVis3zTtHPsEg9x3/AAqx4esfB1xZwjSDp9xbycqgcOHI77TRdeHPD2taWsR8prIKd25snHrk9K5mLR/ANo8dna6hvlTiKO3kLEH22igDvbqz0QeW9xaWhWMZRvJBUD6gYp9xf6NIAl1NZ7V+6JtoA+ma5XwxpN2QP9Oe+sUJHkyErj0zmpNW0W+8Q26BtJtLF432HzXJLLnqNooA247bw9p3m3SNZxxzfew4KHPt0qqLDwkb77SkunCUjBAnXB+ozWDdfD5nh8uy2QnGC08hk/IDpVKx+GccYkn166RY1OSLbPI/EUAejWUOnrYNHZtEbTknZJuUfjniue1ez8Fxzq+qLpvmycgyPkn9ayrrTvB2hTQo4uIi+ACpfaPc9q07ibwVeMq3DafK0QwNwyRQB43oUtjtluvEevPpTISCsEBOSPoOtdtbaVZeINHjuPCGo2k9yPvLKiJK/o2QMg11F74N8OR6aYpLpYoXbIeaVCDntzXDf8K8sILuS48CXOXgbexM2CG77aAM7xToXiDQ4Y7jzrOGbGdkdum/PswGfxrG0PXppIpbTW7q/itUw6gZyze1ej3ula9Dcfb5FuxE8YEpVxI5459xXE65bve20lrbaHqMups2yHzCTkHvj0oAvXFysdo13pfi6+eJgCi3CktH7DP864bX/iL4tKrBaXt5coX27kYx5H4da6vw/wDCjxpIUa/vbS1tn5eBnLYHpgA10esfCO+ubSG2gvLYQK+47NysM+meKAPF9LvvEfiK/i05WuHaR8hVUs2a9Bg8DeLdJspNZ0XULpJYFKS2zErKpHUgHtzXW2vwzk8PxtL4f1MpqpXbC1w+zax64xnP0pbnw5rtlYTXniDxOyamU6QTY3AdARgZFAHjus6d4yQx3k1tqG65yfObc3mVomy8R2vh+J75Yn02H5iFkAYHvkda9z8LTa3BbW8V/dT+Wy4WRoRsA9d1eeeMoora61K0tpYLmSVicqN/1wKAMWy+IU9nbadDokamSLPnR3ChlkHqD/Sodf8Aiyb6YRW2lackiNwkdruYn0JPal8M2MkemvOdHs9WtUm3SQt8swx6Y5xW3r9hb+IoobjTNItvD3kEPHKMBtw9SBQBzFt4y1a/vxcWukWmlyDiRbaPYXP9KhudW1G81YwXKXNvdP0QkgP+dc/q+m+J7nW3v7dL2eRDmUwgncQeuK3L9PG2tQW9xFYYkQBRPNGQR7EnpQB1uhar4ij11tJh1W9svlBW3KqVb6MelXL74f8AirxJq7G9uLa0kQZM4fe0gz1yO9cA+h+N76UGbTb2e6UhXlt1JC/jWtafDzx75TI51ERSfw+fjb+GeKAOkvPg1faRq1leWckmrBj/AKQGIUL+BPI+lXNP8LytrE8uqG40ayUbvtMCkK59B6VVsrX4oaFozW88rLYR4RZTMHkA9u4rrNMnu/Gmj/2PqAcZU75kBRQw6detAHH+Kf8AhG40jm0jVZtUu0kAmku5iVAHYA4/rWp4M1Xwrrt5NdanL/Z8o+RY0l2RHHU8dK1dL+Bug2xja9uZrxlJPzKF6/jU4+CHhGGWeR/tQgb5gpmA2nvzjpQBFrGk/DaWTzdR1dGZeQ32wnGfpxRp+j+AIYmDa6LqIjEayXAKpn+6AOtWP+FT+DtKSSf+zb/UQy8Rbi4/DAFYDeGbXw/pQXTNDvru7uzsdpLJna2U9Nvv70AUvEvg/wAJ+VLJa+LXFyoLxwswYE9lwMV51e614j067jnstQlsLcL5cr2jH7o4ycV3y/B++1OOS5F/cRXK/MILiLaW/wCBdK9N+H3hR9G0y4t9UtbdjJgBThwR79qAPBPDHjiw0dpIrnfrGnM2Ss0O0sT1565qPxLq/hzxNKVg019JR2y2yUv/AOO19G3HhHRNWRv7Y8PadEEPyGPGcfVQKoL8MvBXm/al0m34/iErbf50AfMWn+I9F0ad7Y2D31sh2hndkcn6DtW/oOv3WqXjQWVleNaquTAkzj8foK+kbHwR4WtmEttoenls7g5iDk/ic1oxaBpMLs1vptpGzcMUjC5H4UAfPvhHTtRn1C+jFjqV4kiFVhd28ot6EmrvjDQ9ai8PwwW/hr+zLaDLTXEcu4sT/SvcNc1aw8N6RJI8ltAsMZMcTOE3Y7AVzkPxG0n7LG2okESrk+SpdR7HNAHh0dheC3ifS7DU79mID70YoPYY610OmaJ4msroX8eiT2Min5BFDkCvX9O8ZxXsjJY6FrTQKPkl+y7Ub6ZPSpJNT8Tz+abTQoYVz+6NxcDJ+oHSgDhhf+Nl09I9E06dJM5kMqY3Z78iuU16x+KWuXiLeC7SGI7gsSbFP5d69em1bxYhQf2DbDPBP2jcM/h2pPt/jTzo1/sjTSmfnbzjwPbmgDgNJ8N/EKJ7X7Bf3dlFFgsJ5lZW9RtOa3rnwX4q1q4jXXvED/Zc5222FKEdOBgGvRbP+0C+bwWqpjhYtxIP1P8AhTrg3jW7fZkhScNgeYSVI9eKAOCvPhbFcKqf27f7BjhwHJx6kmrdv8L9DjTEj3Tv3ZXC5/DFdxCsoUGZwXxyFGF/xpZEL4xI6f7uOfzFAHG67r6aXaxjWPDZZm+6kflyr+fb8q5ab4r+FrFxHc6NNBG3BMUSHB9wMV3lpa6Dd3bS2jQNdSjnLsc/QE/yrPh0Hw/oLyWk1oLr7c5cq8AkK+vOMgUAeReKvixbm6kn0H+0DYbMCBmKru9cZ6e1WrD45ahqEdv9j0NDeY2MNpJI9vx7V6JB4B8KX0ry6dbsuw7XVSygf99Cuh0XT4NPmaCx0sWqp8vm+WuCB3z1JoA8mk8Y/FZEe6XQYzZgF9z2+0hfpmvP9X+M3jsvItqQjfxhYRhfpX1kyK0BiumWQPkYYAbh6Y71h3fgrw/dphtNijzyTENhP1xQB8weF4/EfifVl1XUJpbuMsHnHnlceuFz1r23S9X8LWN9BbiJLt3A/e3P/LI9xyDmutHhPwzptlI4tIbe3I3O/mEZ+pzWDP4k8B6HMLZIbeQN85kih84A+7HJoA7C7v47qykjsAt1uXaRE4BA9qqQ6JpdnapJFbNM8HKqVDPn+6cD+defW/xt8H2l9cItheW652iVLcDf+Haty8+MHhmPTRc2ck13If8Algi4cfWgDvba1t0AkjtYonYc4QAj2OKy7/TIJtRhCWkioDukKIux/TOa84PxysJYG8jTpROGwEd+f5VQu/jg8GqKh09o0x80MylfxDUAey2lla293NNBGY2b7w27V/DirbBJkwwV0PY8ivHLT462EzmKTSm3n+7Nwf8Ax2u0034g6RNpwvL50sYTwu6QN+g5oA7FshSVGTjOPWobQztbg3Sqkx6qnIWuftvGukXMHmRNMy5x8qZ/HNcpc/FjwfBrLrG1294xCM6ZCHHTPzf0oA9MmUeWfOKtAF+YMuc/5+lc0txr1pcumn6XayacrfIgOxseuT/hXKa98Thp8Fu1vNHM87cgLgxj+tc34o+JEOqT2dvpmpeeFYSTQvH5ZQj3H3qAPQvFM+uX8EcOmpHbzbf30PnEsc+mK5u58N+KZbSAMJSYvmDyTh2IPYrmuk8J+J11q1c6PYh5QAGlL4VsD36VpWk2q388qR3sELR5V4ztZwfcDpQBV0+w8TyaVa+XrFvbuBgo9puwOmDzVy0tvFFvcL52o6ddwn7xeAxlfptNW7WTUoIEjkRJ5c4dyCD9fesXVfFWo2k0tvDpEzvGQTICTlfYY/rQBNd6b4vbUluLbWrBYBn/AEdrY7cfXqaVrTxn5nmDVNJKDnyltWGfbcTWNH461K0uvP1PS8aTKcRyr8rqfQg9f0ro7fxnoUqIzXyxbugkUigDmvE8HjqXT5Hiv7K2Tp5UEJd2J965GPwp40SOzg1HVLmWC6kz5Ck4jP8AtdsV1Hij4l/2U8z2UcNwE4SFjhnH97NPg+IMeveH55NLufsmpxr89v5fmEfQ0AVNF8AeK7PUfNfxS0FmesMG7OPx4q+3gKWOWSbVPFOqbZGwqxyFB7Z5NXdL8WwW+gO1/M8V/GCxRkJklPYgVzMvirU7+x89LxkmV9pi8nJCnuRigDeh+G3huaZ49Vln1W6ZQc3E7Ege2DXSDwzoFpZLEdPtkt41A+YcAVwdr4h8UWsKTxz6VJpUfyM+MMPdh1rP1b4nX9s80WoRW32Rht3x8H2PJoA9jWRQsYgCtFjGE7Dtj2qlfa5Y2EzJeyNAFG4u6nb+dfMOoeI9TS7EI1WRbeVSwlV9p+hx0rldT+IOoRB7c3hurdG2sr5bP0PegD6cufipoEdyEgM00Iba8yrhV56+prUTx9oDylVuZGXbuDiM4Pt618yadr2mrpH28Q3CEna0IHy/UVJfePTexoguEsfIIRYUj+Z1PfNAHvN38VbK11NoZbCcWjDEUrHBc/Sqh+J97fM/9i6QJUQ4ZnJO364xXhtnqcGo6hnUNSEH2Y5RZATuq9eeMdTstOni064S0VzjC4HmUAerr4o8f6pLJLZW1ja2cPLuE3cfiTWHe/EvxEkuwtFlSRlABn8q4LTda1drcZmF4Jk/eJHIVz7HFclfW1zNcuI7iS3Kn5okYsF/GgD1r4p+OrLTL/xHpVrfa7d6hPLHCscoX7NYMoBLQ4+bd27dT1rhIvHfjGw1WO4L35gccSNGd+PrXndtrupw6umoRXDz3ayCdjN85LjGCSevSu+uPjT471vS5bKKeFhIrLLIlsmQp6jpxQB0w+LutaLayS2k0k5fnZcJnBqKz+OGuSadI1xdPHI55IjBx9D2rxk2+oSWxmvJnWA8FuSang0e6aOPy3cWsnTe364oA9DtPirrUepS3D6pPKOTEXYsUPerk/xh8RSxSMmpykbdvoOa5nRPBRv4v+JYxublD88e0jHv7ita78P6Ulgwu5oYgP8AWBgcj1x6UAcZqXiHWL7dFcaxdy2zHd5XmEpk98VPo1nq6ndayAxnkjJ+YfSuy0qPwfoqWz28NzqdwCG3OB5RH900zxH4h0ltWW9sol00yoI2jiUkIB3A/GgDBj1SWGYPe2jCzj+9hc5+hqxb+MrLSNXkbTNMgu7W4XOyU4YMferun6lplsjC0vHun7/aYsq34Gs5YLDUNV2X8lpZwt83n7SMe2BQBRfUYr3WVlvIP7Pd/mCocrn60Sa/caldyTanewYhGxZBy/tgVuL4MttUZzpt/b3MYBIzkN+Ga5RvB2opfhBaXC72xGzIRu/OgAtvE32cOsHNzz+/P+FSW1xq4lGoW4ju4m4KMOPyqe+0O8tbmKD7ARM/ytuUNk/Sqoa504Fb21VFU8jkD8qANT+0tdUO8F6IC/SGGQkAfQVi3l6bW8/fiKWbb8p2kLn61t2Xiaa1hL26WVvAv8flZY5rI1TxFPdWu15baVGz8hhGR7g0AVJdR1BNj3krpGo4BJKv9Kn03U7R5GZoRBMo3Ryh+p9K5651Jhth3CWIgcEn5D7VXe4iO4wR/ukweepNAHpFh4u1jw5It/DezQySdNr4z+FbOj/EvV/7TBgMUcs77pJt3zn6mvHDcyTk72bd0+c5AFXLW+uUkWKxCBwMFjg/rQB9L/8AC5dXm09okmtYPJGPtH3pHI9ulVtK+Od6YZoru5Vn/wCehjGT7DFfPdhPJLDNAS+/OZChwOvrVe4lkF0GiaNI4+uTQB9TaX8YfD99cQ2M+nxEkgs0p3JvP8XtV+6sbe81N77VtJkj09x/o8liN6M1fKv9qL9lxaBFmJ3GRuDj2FdDpXirW00/7PHqs/kLyYElbj3x2oA+pbIaDDLL5mh3N/eYzueEOqDsDj7tUIb+DT9We6tdCe3SY7FSABSX9a8a8LfFDUPCSB7S9SaCY73gkXeWPuetamtfGe+8SRPHNY2do3RZY8rIvuCTQB6J4j8Wa3Lq0JGlLD9m4klli5wfU10kVxY6Dp9zrQ12ye7mQF0G1hjrtAzmvmi98Van5ckE2p3zWhOWLS5LZ96pmO/uYmNpMt4CM7Q2cCgD0vxD44tTqU+o6QTLePGVliljCxfXFee3ettrVuzX91E04OSMbQPpUDXLy6G9tqbJbuMjGzacf1rjprxDqEULMskMZxuQYJFAG1/bSee8c0SfZ0GGbGS34Vf0y40y7LS21gSU5Qsn3se1ZOuJpxdPsjOJG+93XFUre5ms5Ut4LqFipyjAHg+hoA6eTUrrWN63im2slOAoTaCR7V2Gm+A21iy0i81nUNM0Nb6Qxaesjt5lwVOOykAE4HJFeY3ker/PJdjeerFT8oB7165oPjrw34d0i236pqmoaYbXZdeHLq3W5R59pG5JmOI13HPAz7UAcl411cWl2ukJplubqykaGSdRuJZTgnI4IyKwszXeoI+qB3ULuVc4B+gqjeEPbpcQ38SSSj/V5+57VOtlqEdtE96Q1oBnzk+9QB1Nn4jkt7KQxWsKxopVVLYY1zMnnarI1zNfLZEnAjXIP41hXV5HDqP3pTGCGQNyWroP7fLRof7OWTj7xUCgDm7K4N0St6uxP4JFXn6V0VppsNottcoJySfmA+XI+lVNMks4WSG1juZwcBoZRghvarNza6iLkzW3nRHtG54H0oA1vseju0rmeW3IGTC/3ceoqxpF8kemzNDCLp5MojleI89xWLY2Vz/aaNe3EMrSD5lLfpWrdaxHbW89ha2TJIRhDECQKAJ7HUtY0tfJ+2SRmcbP3QAXHoTUVxb3255JEieFxgl36+tVdJV7oGz1G1kXcBick8fgavSWsUMgtdJvxcwqOfNHyt60AYklnLpwVoZI3SZ8LEvJz6U9bW6UzXP2WRZFGMSchT9Kr3VzJHqBjWHbJGdy+V82SK6nR/EVtNqdgNTtJpIGcLOvmeUzZ4BBIPT6UAYmltMjI837og/MHjrV1/RIreFL2e7VnlAaKKLDDH4dPpXofxv0jS9Iv9O0XQohBcRW7PLKq5Z9znAc9zgfka8gjbUNMnlDW3mw4zhskigDtvC1rc6qgs4oEh43ea0oQqMelaMviXVbIKL28lk+zkCETbWUAVwtgVmQT2ku+6HzAM+PwNXrS8k1e5+zXFrBFITlpHB2D0GaAO1uPGV+t9D4gvLDTphFwiMu0Gs7XvGuqeJIXurbR7FFx86LEGwPxrntfXVnhj01LaKWCRvl8sZAI96oaQLrT75bqJpYtnEnnplH9sUAT+fpesKyXMEdvc4wsaLhM/QdK4rWIXtdoktjCAceYMnP0r1XWPEXhz7NCY7GGx1DP7wwpwfesu71nT4dOYXcMN1FKCUHcHHWgDx6YMrs4ZtucEinCyk2tKCyBRnDD71bMmj390WuIbKTyCc8fwr2rN1G0nALPLIApCmNjzQBTSMMdswIYfMNuSMda+rL74c/DyHxjr8drFHujspbePSlnfdBPHGZGnPzZ27fKAySMs3HFfLWmXTW1wZw8sUsXMckbbWQjoQR0NXIvEGqvqM+rrrGpjUpVKS3YuH851IwQz53EEADBNAFJd5QiKRUB9Tinx7gAm4Fgfm3HIxUCoscDF13FujegrT0uLTpbVo55PIuByrj5gaAHRaNcXIEkS/IvORWudKgskt5bu7wH+/Gn3vzqpALmKBtt2hXHyBG+8azbkvcIrFz5iHlWbFAHRf2jZwoIobWKJN2Vlcb2IqGa1trtWMck0cznKMVwv8A+qudSSSSNhKMKOAf/r1ejv41jVP3oKrxuPFAHX23hiCTTGN7cmOcD5XZsqfoK0fB1nNel7DT0d5eirjbkeua5CHxWY7BYoLZPtIfg8tn86kj1zVLzUWa3kFncKmQQ+wD2z3oA6vXbCytZ57K4mZblRtZ2O5c1xzSHTI5gltDcgnCXDLwa2/DOpxzxzw6kIJ724fO+VuBWvqGpWN9dJaXmmLDZRAI3kjP40AeZRTyl5HFwiFj8wxj8qcrlLtRaMjlsDcf4jXaeIfCVjOWudFRzYxDBZyAD71i/wDCKQpGol1K3SVhuVUOcfjQBYb7e0BtUgE1xIOdrE5HvUdpp2o2cRt7xPJWTu4BAqymnXkMIksZZyQMDsD7il0qxubqcz3VxHkcETOcigDFa0isrwrfSbVP3CBnNdENFtZ7Avc+IVijC7lj6/hipr7RrS8nQXCoxUcNG+QfzrTXSvDdpabrqaKSY8eSe340AcZYw2cylJpWYocBt2Mj2rUijt4UCafPdMnVh5ecH61vR3vhGULb3Fqlvs/ji5JrIm8T6Pa3MsdqjrEDxkdaAK6xSpML6cxCaM/OhOCxrf0O5m1S8dtMjkmuCOI2G7B9q5qF7jUIfJSNfMH8UTZzTrO/vrCULYI9tdIfmbcVLUAdDqN48U32XWLGKG6zkFFwcjuavWmsWFlAjpnzicbimB+dYzzLqEJnvrjdedSsvU+2ajElzqVmwtbMiNRhiWBCj3oAn8U+JIZFESRuh24Do2efWuOjurmWYpDclWXt0Brovsd0sR3RQXMCjlFIz9a5bV/s5u1CRfZtvBAbcW96ANzR9Rk07WYL2zT7S69Yphnce4r0PSfG0L6yuq3Vlb2U9unlGH7Mkm7kHIDAgcgc9RXjMtwF2eVIVkUfK44rQs9UnnB8+B3wAvmDt70Ae0ajqt74jmn1a4kUK3HnOw8wnHAwPauSk8RQWcFzZrp051KQkGTdn8QK85ae6e8P2KedVU4UE8GtNrWcyGa5vT9pI5b0oA6TUbO4azh1NbSKyhZtjYbGTxzitKeGJEigsL1p2YBppMY2nt9a4WLX5bEPHOiTqeEaQkj64qxoPif7AGMsSSrnO4HFAHZX9lrOlbYvtcayyrvAD5OD3HpWPMdVuJNiyyLEoziQ5Jataz8QebKmoW9tbhpVKtE75x7+1cvc3s1xfSS3N0zW2eBGOVoAntxdvqCGeKOUqcuGGcCpvEKW2oygrBMtvEMO0Ix830rOsdTeNJRCWbPSRkzWhHNcxol20UXmSDh15BHutABp1nM8RWwuZJBk7QcjPsadqWmafp0duWulmnc/PE65K+uTVu51K9ht47u2NusBbGEGGFU7bULWSd5bizLPJk8HIP0oAzb7T7SVv+JSyNGx+ZXXoaq3Phe92SySeWOPuxNn9K620urTSQdRtpYBcFdv2Z48jHvVSxebUpvtKFUUvu2j5cn0FAHG3ui3tpbma5jMcI/hlGNw9qr2+mTTp5sEBIHIw2MivTPEWr3d8Ettdu41a3A8mER/eX03Vy15qFpO0Vpap9niBwXzmgDk5N53AYhVffoab8kyKokLMv3mJwK19f0y0E0cVjIZZD94jnJrOtLV1maF7TzmzjIyM0ARSSC2YAPuXHYZGajhv3ijPyK4b+8OlP1C2aN9qxNG27BUjNVLmOWJgswB9MdKAHQvK0rNH1744xT57yR4xGzsQpqqoYAEHG7jrinK+FKONyj0oA0LO8KROkewOf4m/pWlpviKa1DRSHzx2J7j0rm3IIBVNo6UI5TO04oA9I07XZLmdJ4UVLKMYe352tT7yWyn1NTcRtbxXXCYGPLrhtK1e4sXAhfYM9cZro0mi1bTy9w7G7ZtobPC++KANq/0XxBpqebBdloEGYyDwR9K5ZtXuzeB7ssxB9OCa3Ib/XNMs3sbiM3UEi/IwbcB9K5W51JniaJ4iCDySOtAFu6v33bkkkQnllz8tQgPO3mXXnGA9GBziprO90eawEd3BMLnP3kPUVq+H/DZ1eScxXS2dpGM7riUDNAGFNNYrGVR5WkBx2FZ/wBn+0MWj6e5rf1Xw7cQMWhNvLF/z1jcEGso6RdIfkkXnnrigDurY2VlIYppnhmU/wDHxDyPxFUdau5JZybe4F3GP+WkkeGrTg8PwXcbG81ePcRnCLnNYd6tza3P2C2nUW4OMsMZoAX7dcXaJE8EckQ4CKOc+5phmv7LdbpG8W4Z8pGOAvvUmq3U9iUXbCAVA8yFcfr61YsNZCWskOxyr8PI3L/gaAG6VpHibxBdQxWNrNJLL+7QRLjcPwr1Hwx+z1qk8Ru/F1ymmWMOWmAcM+0DJI7V5laeJZ9OZTput3VpPA2Y2UlW/Sp28W+KvE0zwS6leXZYYYmVuR70Ae5RfB/4ZWWmpqlzrbXGmFtytvG4+3H+FZcfi74S6VqjQReG5pLM4j84MTjtnaW/rXhbPqFhqMEd4jXEELhmtpZGEbrnlTtIOD04INes+PdG0hLDTtO0zQdD06a40q2vLiffMZY5pPmZY9zkbcBRyCeTQB0F7pHwh1WRvsuqXdnIELoCMKD+VeVaqNI3vDa3/mOhIw4GCPY1nX/hn+z7IzTXHnrjlYW3H8q5C8tYlHmpM6Ef8s3BFAGnqdjDczEhWhiHQn5iaxpw1uph2K46gCpLLxBf2LMkbIyn+FkBH61W1K/N1IzMqiRjksvGKAJ0ubdoTGoeObsR/Kp7C8dHC4KI4wzZ5NY8cgiYkYZj/ERUyXGw/PGCCeOaAOt064ttPhbZLKtyeQONpqEa7qFvK0dqvzScMdnUfSsOa8ikCs6NuBB61u6dKJDmMLCAmdzn7w9qAJrOZ2WSO2R0lK8ox4NFuyDyo9jpdhtrYf5Me1S388MqKdLUnb99m7n2q39vsrSGG1ey8h8b3lLbm59qAG3c1rYXKqbGaaVhlw+SD7ipoNWQTReYzwLngog+WrEhnvIk+xygyDkELg7feswzzWF15WoBZYmb5jtBNAG9eT6bMoSaRryBujlfmDfWuauNBvLqUraWcv2dDuMgUnYPetK41RZMQaZbvDA53fMnOO5qNRfTzNHbap5OBhvnK7xQBQgt2tpcC4iYLyCOCfY1e1ebMcNzGjRTqMbAeG9619Gu9C0m3li1C3W4nYHdLN821vUVzV0s2qXLjSmL88IF7e1ADrqG4ns/turrFDGBiJkP3j6YrIvotPm0dZN7LcHkIO1adzYxvZ/Zp0kR0+ZhI/GfYVz89sgt3B+8GyMNzigDIP3fvZ9qbUsyxlh9nDkd8imRsUY84OMcigBuTjHOPSipTETGNsbFupPWmOjJjcMZoAbXQeGri4sL2KVI0ljJG6Nj94elYCqWYKoJJ6AV0vhnSb2+vYo4be4kkBGNgzigD3jwSnhPVpZ/7bhOnytD/o8AztLd+T3rg/FPguwmurr+ypJnVSSyEfMD7eor3Pwt8F47jR7a612bdP5ayIISSy+3pXf2XgXQW+xi5s7dLyDllVsu6/7X1oA+ALuwnsbxo2iZSvTIwaoNJOM7mbnqM1+jmoeEPBuqzCK60rSpZ14wqqrj/vnBriPGvwk8DXllI9rFbWN1EPl2tlCfRv8A9dAHxBb3ssKECVsE52iuk0DxFawRSi/tzM5IwfQV2njL4SatGPP0yzjljbkNByuPavMtR0C80+5MNwhRx1BFAGjYXd1psgeaF0I4D54Fb39pWEluzXcP224kHEgOAlYcg1gAIySeWwyBOuMis7zby2nKAqg7qOhoAsNcPbzbvLDxlvlUnpVufxFLdqLeSKODb3UcmsC+mkuJ1Z1PH92q0jMSQARj160AdHvQQbiEEmf4lzkVDp2uS6TcGbT5fKnbhsrkVkobmdQi5Yeo5qSDCSeVJChYDhmoA6WfxDJqNuzXt0u9RjAjGWH1FW9W8R3eu30mratdGS6dUjA2BBsRQqgKoAHAFcdKgBBClWHAA6GtQWdx5EdwVHkcISR0NAHS2OsMro1o8cZYfMWGcD2p+s63DPp32RoWltz0uTENynuPpXHzmS1unjnyAvAC1etLoWlmk0935sLH5rVTnj3oAbLpUPksyXcOcZCvxmucmUpIQy7T6Vo6k9o7ebahwhP3G7UGP+0MsHOUXhm/lQBmhcjJYCm0MMMQeoOKKAHJt3Dfnb3xWtp9wttKhkDPESAwz/D6Vjg4ORWvYiGYLCLQea3ALE4oA1YNW2XUzWyiKBzhUxnirVv/AGVLKpu7iaWSTgBeqmq0VgIQgnMMbN0cHPPoa0F8qazEaQ2QuFPLRqd7CgDTsom0n51SUK3/AD2ONwro9Z8N2p+H2lavPEY7y7vbiOR2lP8AqlVCuB0HU1whiu7gtHmV3jHG/kD2rtNJ8X32neHItL1CDTbiwjkaRFurZZtrMAD97nsKAMfTr17fy7aGYGInBLDdgVdFxpWlTn52nVjl4mTp9DUEN/b6ZIIo4Le4sb0HPlfejPqPSq1xY/ZlaTT/ADxaOcGSVQTmgDQ1C3t7i0lvLSK0kt1XzDExwxrn9JhuZg2pafMtiEyMNwBVn+xHe08o3R8+U7vM3fJj0+tMn0q8ksfIecySkYWMcD8aAJL7xAG8lbpo7xI1O50TBY1iMsF9GJXi2wHO0J94Gn6tHcWccMX2VQyKVbcME+9VreFLcF5JwjYztQ8UAYlzutGMboVYnIIPUVSkbcxb1NWLp3SRwyfKxyA3NVxl2IzjNAG1oVuWjNyhJMf3hniui0zwNeeJ7KTUtLaMQoSJC7AYrk7CS6tAXiYeWRyGGQ34V1Ph/wAQIIp4C/2a1mGHQNgfgKAL2i+FIrW0mW6iia5YgK5f7vvxX0N8EtI8MeGbY3N5qEb3UihsSDhDXy/qmrfZ7I20E6kIf3YBzj8azbPWJXQ/abqYMOFwx5oA+w9d+Mum6JrV1HYReZajCrz8jN3OO1cd4u+KMuuXXn+Hbw2ZAAnUdM4xnNfOC6qJ5tsiMAeCxyRWtpV95Op5t3CIRyoPynjvmgD0V9B125vYNTsro3rzNk+VLyPw612NpealdXMVhr88qaSgO9E4fdXnvg7xrL4d1ZrqRIjORtjdTkKPpXo3ivx/dah4fif7FZS3TjO9FwcUAP1Px7pWiWLWNvPLErZRSwyAPWuL1LVfBpMbX0z3szZJcHGPavLfHWsTajehpIxGV4IFcr5jYxmgDuda8TeIm02O21dRNEihVdkB4+tcpDdwOzi5DBD0x1BqvLf3UsHkyTO0foTVagC1M6tzEW2rxkDFQlg64z05ye9R5OMZOKliyP3mzIXrQBNYSpEzF3dT2weK0PtMcxZUiUycHc3eqb3Uc4ANvlh3FJbRRyNkTskm4YGOlAGrLdmVVSW1EQQYBHFN8/ERDzTGJuqMeK6GDwtbX9mt1Nq8cUijlJRjNXtPtdFsrX/S5oZW/uk5FAHKr++Qt5ZkCjoWyazjJNOhiRFjHICBcsa6bV9S026tQlpAttMOCYz2rlp0eOQuXZk67hwaAK09rcwLiZGVfek8p0GUkBbGSoNJLcNKMPuK9stUAJByCQfagBz/AHuhB75ptBJJyTk0UAFWre8liBCkEnu3aqtTRQSsvmKhZQaAPSPDmi2UmkxXF68cjtzy/T8Kz5NL86SRdPlVHBI+/gke1P8ADl9oCoi6lDdKQOWj5Ga07gW7B7zTnRbKLpJKcNn0xQBR0q7ngs5beOFftBb7znk4rGvPOumeaXcecMm6uk1C4064tFczNJfkdI0+UCs7U5ZZ9OXdZeSEH31HLUAZls0cMZGZDuHIUfdqw1xd3SwWtlPJsJyVboPc0zTYNQLlorR5oiPm7VYmvI7SPyJLNkbOdwBBFAEkOhTtMPP1ERIDkuzYXPtUOsSNHGsMl4WZWx5kTZ4qgb1GkdJC5hOevasV441mLQzB0zwvNAHSXd3py20Je6lvJgCMHOU+pPr7Vh3v2RrdmSeTzCc7COB+NTvp8BsxNNeRws3/ACxXJNUI7aG4kMcM4C/whhjNAFWRjhCzBwOg71ETznp9Kmnt5IHZWwdvBINQjjBoAsNNuhU7mEgPGKjEzA9j+FWLW9kgZnMauGGOVqrK5kkZyACTnAoAaTk5NFFFAFmG6eM8AbDwRUaylXJQtk+9R7jt29utelfDBFsPBfjLxHYWtvda/pgtVtfOiWYQRyOwklEbAgkYUZION1AHAx3hRlJG4j+9W0uv3QtAkEhVvTtWh46k1PWG0jUtb0S30y7urPes0EKwi9XcwEpRcKp7cAZxmuWto9zSeYjHHAxQBfbSNV1GFrlLSZ0HLSBSVqKw0G5u42dVfg4+7Xpfw4XxFNbR2uks7wSHDw7QR+tbGr+AbRb1/wC0tSuNOuDy0RiOP0oA8JuZmnmZ3RVY9QoxUVOlkaVy743HrgYptABRRRmgCSPaFJLsD6AVZeTy1VsAsD94cEU20SeSNhHgp36VHEjK7fIWAPCmgCxLfS3Uv71mcY4z1qm+7d84YZ7GrKQ43ySIytuyAOmK2dOksSHWSMAgZDOf5UAYLxsGVog+fpTXuJmQoztt9Kv3N2BKcTBlJ/gGKzZGLuWJzmgCS3eNciWMMD39KLlomI8pNvrUNFABRRRQAqqWYKoJJ4AFbVhbajZjAtHkWTjbjNYqsUYMpIYcgiuu8O6m91OEnlkiAHyup5JoA09K0LXLhQ9vpzsAfmUISVHrimapYrcTKhP2dE4k3A8t9K94+HHxL0Tw3FEmupNE8q+W8gQEEeprI+Ik/wAObt5JPDF802o3ZJYFiI0PryP0oA8Q1G8e3cW9lNC8acF8YJ9hVmx8QSrE8ckPmxgcgVR1XQbqCYoIRLg7mkRgQa1LLQ9Tm0yS4sNJmFrgFpVjZuR7/iaAMyHXNQsbt5tPWby2PKP0p2s6zfXyxm4RY5Cem3tUCX0sc3lSo3mcjDrjFU7mZN5WYGR+uVb9KAKsyyTErlOOSc9RSrEhw0DLGQOc96CsTupEb+V355qKWeKFisA3g9d46UAWVhac7lAYDg89Kk1S20uG1VrSeQ3HGVPY1UsJz57Kj7A3Y9Knkjs/NLFw7nqtAGa6s7BQCWHfPWoiCDg8EVsSW8E8WLSJkZeWY96yXUxuVcc0ASEl4xvYDmoWGCRkH6UUUAFFFFABWn4d17VPDepx6jod7NZXqAqJYWwcHqD6j2rMqWBFZgXPHoDzQBtal4p1bWtUbUNdup9RuXwDJOxY4HQD0HtTLC9DXssphBGOIxwKpGSF1EUcbjB471sHRpfsaSwMdx64GDQB0ml+O77TLApazS2twOECADFZGp+JdT1aYT6nqN9cTeoGcVp+EfDwubiOWW2nuJAR8uM5r3bQtNsre02N4ZgibAyJo8sfzoA+QqKKKACiigdeeRQAAleQSKmQmUnfIEApJHWTGESMD071FQBMGZl2eYxJPHPFPgg89jGXUMvOSeMVWooAsRRwbGMzsD0UgVDIFVsK24etNAycZAoPWgAooooAKUnJyeaSigB8Tqp+dAwrd8P6nbaPqCzYWZcZG4ZwfpXP0qKzsFUEsegFAHpGveN9O163EE2mxx3ONonVsLj6Vk+HfDUutXqxJeW9rG/CPK+Ax9KyY/DWuXcKNBpdzIOwjjJJ/Kqt3pWrWH/H1Z3dvs5O9CuKAPe/CvhnWESC3FlbvOjeWp8wESc9a9zvfHNj4M0BVvNClsJF+U28QHl57nI7V8Qw+ItaWCKaG/dfJ4QCTDA+uK6jQ/ixrseo2zaxcNfWsZzJDP8AMrj3z3oA6Tx/rOneLNduLya2FtLO4aMRxYG2sGLQdNtod+oBjJuyqr6fUV1Gt/Evwbqt9Fcw6NJby7QrRpjYT/SsPWfGmmKkiaXpqxSPgjfzg0AVLp9IEotNJsJFDqCTIdxLe1U59Bu9Dsl1GdbJ0nOFiZAzj6jtWTe3N7MVvY5kVk52qcH8q63w1eXjaS99K8dzg5VJAGPFAGDYeENb8RmW8061gMK8spIQD6ZrGurO6tp3gNmpkTIYKM4/Guutmvdc1aGdpLW1gkyNiy7FH1FZHieZNNuJbSylR5gcboX3frQBy0shthhgyh+qN1qCVrZ4HChjOSMegFNuXmmmb7UH3e4qpjk0AKxPCkYxxWhpF9b2bP8Aa7RblGHAJxis/acZwcetPaCVVUtGwDDIOOtAF9LeHUHJgKQNySp6AUxdJuJZ0itx5zt2QEmodPuGtZxKI/MUdQRxXX6H4gFtrlnqtsiQT2zKwQjIJHNAE+nfCfxVeKhXRdTIcZBW2JFaNx8FPF1hD9r1DS7iC0XksQCQPoORX014d+PegXulxy6pb3Ntd7R5iRBXXPtyKvQ/GbTX8yQ6Zem3Y4hdADu/3vT9aAPlq38GXDp5FnaTSt3lMeCtR+KfCt/omn20lzPiJzwS3FfQHi7xNrupWv2iy0QW8bnbJLCpO4HueOteZ+MPB2rzacs14t1JbsdyIUO3n3oA6P4N+JdG08W0NtpjzaipAJaT5SfXNey61JZ30sc+r69b6ZMVwLdCrYHufWvk4fbPDRSaSVFtO4jYb1NS3WoWmpssyamQcc7nwaAPH6KKKACiiigAooooAAOM1LiHnl+np3qPoeccGkPNADnVRja27Ptim8Yxjn1oooAKKKKACiiigAqW2uGt33oBu7E9qiq1a3hgjMZjR0PqOaAOr8MfE3xN4buY59Mvirp/eAYEehz2rV8TeMNe8YvLeavLAZpkxtHycfSvN3Id/kGM9q+gviVLpPhHTItGs5NIXULPTbaGezl8PrLI0rxKXc3TdD85PHTGOtAHiWnwwrMftjquBxt9aiYO4lZbQyqcgPtPFFncWCf66GRm3Z3ZzkemKt2uuSW16ZbZcQKeIyc8UAYwibBJ+UjseDSwzvFKrjDEHPPNdJrGsW2osWeGOEMuDtUVzMiqJSIyWXsT3oA6qws59SiNzCImkYZMSqSQKpN9utbkLb+cj5wI1zz+Feg/BrxJrdvdpY6LYWRkHytJNErcfjXoV1rP/CNeKYn1HTtKm1i4H7uTy18uP6jpQB4Pe6LrFnbxvqGn3dv5hzHI6EA1TspZLXUER4jHc7hhyP6V7t8R/EHil5Yn8R3FnLZyA/ZxHENiflXj+t+fcXH2hzGZ15VlxyKAOt1mOLStCM9xpqzTSdZZFrzHVfLbMkdv5Ib361LqfiDVb2IQXtzI8K9EJ4rKkmkdFV2JC9KAHRzlIyoAB9RXT6f4jsk05Ibu0DypwCB1rkqKAOwtdY0SKym/0L96+eprBi1BFmcNGGiY4BI5ArNooA6DSp44ppHWQLz8oJyDXbaF8RptHt1t1EU/zZ2MvFeWopBwA2/tirdnJFFdqXUsT1B7UAfUekftDXL6Y1umlWZeJdoycDH0zXEeLvjBrfiCzNhKfKtwc4j+XFedx+GtVuLL7fZWj/ZmP3wcisy9t5YFCGUtMey9BQBNd3r3JcCMsM8ktyTVKPTbmYs6NCAT0Zuaz3W4imKnKuTw2alRbog7jk/WgDNp5hkCbyh2+tMpd7bdu449M0AJRRRQAUobgA/dFJRQA+PZu/ebse1OKRrIvzFoieSBzUaqWYBRknoKVkZWKEEHPSgCSdI1YmNgy9vUVDTnChvlzTaACiiigAooooAKesTNGXGMD3FMAJIAGSa2tD8Py6nqMVrLNHal+hkOKAMZSVYMMgg5B9679fiHrOrWz2HizXNW1LS5seZbyXTMrYORkd8EA/hVbWPBEmn6lJZQu906LuOCACfarfg/wfp+raglpqeoR6W/8XnHj6A+tAGJdpot5eiO0RrW2AwGc5Oak0LSLWO+lnuZILi2g+YoZQu4V12s6JpGl6jLpVtLDMVXInY9K4mSxsIfMS6u1STceYzkGgDf1u58Majbv9ksxpska7l2uXD+xriLTynuCJImaPPY1LJDb7mUOUjPKs3epbCyuWhkltVYqo5JoA9H8A+H7WWwnvFupoWVS+A2MYrTsPFGiS2E0V3a/bpweJJWwePSvJbTU7uJPJjnkRW4ZQxANaEN1Z2aANbB1bljnlTQB3Gp+PEm02SwktkeBfuBz92vLr28LzuYjhSeCK2brXbGWz8g2Kkj+JT1rnHILsVGFJ4HoKABi7KN2SB3ptGTjGeKKACiihTg9j9aACnRJ5kirkDJ6mu9+HngKy8UyBL7XINOdx+7Rhkk+leiN+zXryK09tLb3cQGV2yBdwoA8IEclqzBSu7sRXcaDH4OisBLrLXUmo4yQOEqte+ANfGtyWMmnTwyQsQwKngDvVtvhprkqKP3ax5wC5wTQBHceIZcG3smlh0fOCAetctrd7bvKVsd2P7x6muy1T4cXmh2yHUL63ZW58qOTLL9a43VNOjiB8hXLZ4J70AZ8UjFR5h+Ud81ObmQ42lQvaq5tJVZQynJ6ira27R8LHG31PSgDMooooAKKKKAADJpzKAB8wJ9BTaKAAccg4NKAT0BJpKsrLL5RYSgAcY4oArUUE5OTRQAUUEYPXNFABRRSxgF1DHC55OKAEq3ZvcPLmPzGcdCDyKZNEq7VXH1zya7jwv4J1O/RJrO2uJkbGRGhJX8qAOcVdZujulmmUYxudscVZsbO6uLhIJpmDk/K7dCfrXsP/CqdSaztZXa5JLjMMsWzH4mvY4vh94K0Tw+lx4iitprvZlFklwQccAAH170AfKP/CJ6pM7M9yrEHDZfmtKDwt4UlhEM99dxXnRpCuU3elfT+mfCbQdXs4rv7LHaiQbt8Mhcn9a4bxp8LtJfTdWn0zX7I3UOVFsCNzHPTr1oA8Q+zWWntLawQx3yxdGlwD+FcbqV1J58jQ5gVjjy1PFek3Xw11LSdLgvLspIZcny0kBYCvPdY0mazuirRybn5CupyBQBkb3cBR254FN3NyNx5681em0+e3xhuq5PaqQUlC3YdaAEbHbOPekpxG3+6cim0AFFLtON2Dj1xSUAAOCD19qnE0ayBlhHuCcioAMnA60EEHB60AbNpa37IbqItDGDlHBxium0X4heLdOeGGz1u+jyQvExxXPWEOoG1DyMyWhxyf8ACvSPh34N0rXUYarqUFoi8xyOQpH4UAT65qPiqEpreoXxMrqFabdncvvXTeHvifo2nacE1/TZL6duEMbYB98VyPi+ytLOK60+DVDeGPhSDlcVwEXnxMGA3g8YNAH1Vp3jD4fa9Y+U+lJbXTAASXS7gp+tec/GCx8JWmnA22s28t9n5I7aPCAV5RdasVtDBJuifHQd6wJc3C7Bu2+5zQBtaclpcYimVjJ1DA4zSyaYzSt9l2lR1+YHFULQxae6MZjIx+8orUF3oiDKiZXblue9AHF0UUUAFFFFABRQoywHqcVfn0x4Yg7TREHsDQBQopXXbwTzSUAFKpGfmGRSUUAOR9pJUD8aQMd2c4NJRQBJKxfDFlJxjioxnPHWiigC1AwhUs8YZweM16f8NviZeeFF2JeyxA8lTyK8pQsflH15q9Ax2kPHEwHIz1oA9w8Q/GDxd4jtfJjkSCx+8rInztXJf8JhqE8kc2uXbXCxnaFkPOK4gareSW6w7RFEONycYplrJbzTJHJI2/PzM3IxQB7bonii4S28yDVrhNNPJgExGKpzeI7e4upZopIXRDu+U/McevrXmGpXwhj22aRPEvG496givAluXjgVZMdVb+lAHsGhePLByxurZbz5srAOoNdjruu6ZrGiB5PDml2swThpeHX8a+XrW7nhvhPDIUufvDb0rc1fX7i/sAjmV7puGAPFAG/qOl2qW811fNDcMzfu40fp+FZJ0azWHKFBcSfdiIrmIDcRsnnF4ynIZs1oNqF9esq+ZGuzgPjBxQBVv9LitJlSWUGR+Aq/wmql1ZpaKPMdZGb+6fu11Mmk+ZFG80gZm+6x6Gs/VdPlsyJPLhAXuGyGNAGKkRCDLMU7rjipytoYnC7fMHrVmTU2u7cWogjj9SOprFlAMpEakD0oAkkkiCbY4grd2JzSJMByyDPqKjYEDBTFNoAtrqFwCMuSo6KelW4bi4Z905cRnpg9KylGSBnFX7S3kfG4yMgPRRmgC497G0ajfIrg/eLVoW1w8zIkcTyMD8rg5qGS100x4ummjc/dIHAqBvstiwFtcl27EcUAat5qcRRoruyjldeCQOaxb+a0eDFrGYnJ5BPSp4UvJv321grHBkI4/Os6WPdfGOVw6jklTQBJp9vc3ILRKrbe5NWU05ZCTOdj+1FnJGtwqQsyqDzk8V2kFlp0sKPJHliOu6gDy6iigAngDNABSrt/i3fhSUUAK2M/LnHvSEnjJ6UUUAFFFFABSsxbGTmkooAKKKKACiiigAoBIOR1FFFAGpZ3UROLlVYdsUkrQyNxEIh/eWs1FLHgEjvgUodgcgnHvQBOZE3bU3E+p6VYWAOAYcvJ1PPAFUkk2sWIyf0pWf8AeZQsgPXHFADmEkTFpEOW6GkV3jQsDgt0PenSJL5QYuHTPY5qKSR3YF+cdBigDRW+vUih6mIDrtzmiOYG+jnAacd0xjNVY7+4jV1jkKo3Ve1CrPERKTgf3hQB3Fpqdrb2xa+tpBbH7qYzg+1YVxPnUhPHGHt3PyJIeAKzHubm7AjNypUcgMcYqrM8zELJL0HHPFAHRM0bTmRYYom74HFUJGjWcGVAJFPTH8qhtb6ZYjbyovPQsOaikEklwWd9+0YDE4xQBs6jexanCALeAOoAyBtPHrVzSvCkuqwia1e1jA4KOcGsSC1jRlDuxd+QynIBrvfCVydNu4mu8SxDGduB+dAEV18MbmytvtbXCqCuQoTcM1TZbzQLdIzEiiUcOAK+rPDninSNd06HSxpDLdJGAu4Daw9c1lXnwr0XUbl7K41eOO9nJkEKruIB9KAPAfDkEOpny5tOe8uXOFwnyj34r17w14W8CaNoslx4z8JyxXAbhzHI6uPUAHitiP4XWPg63uJYvFPkKgyQQN49sVuS+F/EmpeGFmXXxeo8e+CKUAZ9BmgDyrxTrvw5Wylh8OeHboz5IEThgo/DJrze41DSYcNNoENrK38OT/WvRNS+HPjG2Z9RuLKG1QHa58wZf6CuE1DQo77UWtpruJbwnkSE5FAHL3lzpnnFzDhSeiCpz4g0WAKjW08mBxztxTNT8Py2F+0Iuo2Qcl1GQKw77TB55xKJc/xUAYVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRg4J9KkgMYb96u4fXFACRSNG2VJGeuKkh/eyFdpIpZRC+0QBgx65PSkhil8zEZ2n1zQBLKIAoUh1z6VBhZGCrn0BNWEZXZlkhMrAckGojMNm1EIYdT7UAMlUwSlQ4bjqp4qMMVOQeTSthT8pyCKbQA8AFx5pIB7gUjHAKq5K02igBW25+XOPQ0mentSkEHGOaNuGw3GOtAFiO5YnEjfQ46VZuIo94EMplJGWzxis2lAOQVPOfxoAvWsjIrsCEdeM+tXdMvHWMuxabJ+5nkViYLPyeSe9XrJmt7jzYiNqjGc96APYfD3je/TTorW2U290gxFJ0YVPpfirV1vZZrvVZf7VV8pKpwfpXmECPg3d05lVuRsfBFS6RdSQ3Ek8YY4Pyh25xQB6xq3jtNPkM2oQXV1qEnLNJynNVLLx94mLR3MbZto/wDUIhOFrnv+EqneFlvDCUYY2MgYmqbeJIYozHaRoWJwdpxt9wKANjxD4+8Vanek6pLeSIB+6QucKfpXCtcajHf/AGiYyrPIcliD0rc1e/tW8h0ldmByxZs5qlezW+oyb0vPJYD5VNAFHUdVug2yPeN/Uk5zUFvGpTM10sbnqHBqpfz3Xmral1cg8SED+dRTWd4XzMpZj3HNAGVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUqMUYMvWgBWXhWXOD/ADq88+6FFaIqy9x3qtaMDcDfgA+vapcQZkOXc9sHFAECylJN0W5B6A1YtSY1Yvbl/U1GkClC3f8Auk801Ll4nJj47UANlxJITFGVU9qiPBxUpnds5I/Kohgnk4oAOh4NHf3pyRl84IGO5OKRgoHByaAEHJ5zSqGIO3oOtKQNgOefrTaAClViucd6SlwvYn8RQAlWrZcxOVcbj/DVWigC6sksIEcmR756U9L2RyAcErwGqgWJ4ycU+BwjEHoetAG1Lebo0hWVCWHJYciqqNEodWJaXooXvVYWysN4Y7KuwCBiJYhtki55ORmgCGWNI7f9/vEhP3fSqwlU4OSDW1/aKySB7uCNiOmBWTeEXFwXt4Agz90dKAGJKXJUguexPapYpJkBEksg9MU3KlgqlYWHXFR5mLN5bFl9R3oArUUUUAFFBJPWigB8SB3wzbR60+eFE5jk3Co0Cc72I+gppoAKKKKACiiigAooooAKKKKACiiigAzxinRbN37wEj2ptKDtbK9umaAHE7ThQQR3zQI2JyeB6mgSuDndzTWYscscmgAJ7ADjuO9JQCR0OKKACiiigByMoBDLnPf0pDt2jGd1JRQAUUUAZBORxQAdeaBweeRRRQA+RkJHloVHuc5pE24IYHPY03rTyi7c7x9KALsF48UXkMMrjqBVZGLykLkD+7jk0OoRVaOQMSOhPSr9hNaJH/pJcS9mU9KAH3LJJZojyMjL/Bt/rWb58kYKKflqea8fziC4mj7FhUk0cTBSJoST244oAzwd5A4GTU7208WAxC+nzUqwxbuZEI+vSkMUbk4mAA6bjQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the thyroid region in the transverse plane that shows the local anatomy.",
"    <div class=\"footnotes\">",
"     L: thyroid lobe; I: isthmus; T: tracheal ring (dense white arc is calcification, distal to it is artifact); C: carotid artery (note the enhanced echoes deep to the fluid-filled blood vessel); J: jugular vein: S: sternocleidomastoid muscle; M: strap muscle; E: esophagus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24672=[""].join("\n");
var outline_f24_6_24672=null;
var title_f24_6_24673="Punch biopsy";
var content_f24_6_24673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Punch biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin is stabilized with the thumb and forefinger and stretched slightly perpendicular to the skin tension lines. A punch is held perpendicular to the skin and is rotated into the skin with a firm, constant pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Alguire, PC, Mathes, BM, J. Gen Intern Med 1998; 13:46.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24673=[""].join("\n");
var outline_f24_6_24673=null;
var title_f24_6_24674="Rx MS moderate severe sx I";
var content_f24_6_24674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79292%7ECARD%2F57298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79292%7ECARD%2F57298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with moderate to severe mitral stenosis (MS) and moderate to severe symptoms (NYHA functional class III to IV) - Part I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"     <br>",
"      &bull; There is controversy as to whether patients with severe pulmonary hypertension (pulmonary artery systolic pressure &gt;60-80 mmHg) should undergo mitral valve replacement to prevent right ventricular failure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with moderate to severe mitral stenosis (MS) and moderate to severe symptoms (NYHA functional class III to IV) - Part II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 469px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"     <br>",
"      &bull; There is controversy as to whether patients with severe pulmonary hypertension (pulmonary artery systolic pressure &gt;60-80 mmHg) should undergo mitral valve replacement to prevent right ventricular failure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24674=[""].join("\n");
var outline_f24_6_24674=null;
var title_f24_6_24675="Patient information: Medicines for depression (The Basics)";
var content_f24_6_24675=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16163\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/44/40640\">",
"         Mood disorders caused by problems in the brain",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?42/3/43069\">",
"          Chance of side effects with certain antidepressant medicines",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/5/4178\">",
"         Patient information: Bipolar disorder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/32/32257\">",
"         Patient information: Generalized anxiety disorder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/482\">",
"         Patient information: Serotonin syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13413\">",
"         Patient information: Depression in adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/21/29013\">",
"         Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/24/21894\">",
"         Patient information: Depression treatment options for adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for depression (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medicines-for-depression-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H21736509\">",
"      <span class=\"h1\">",
"       What do medicines for depression do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Medicines for depression, also called antidepressants, can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Help you feel better and more able to do everyday tasks",
"       </li>",
"       <li>",
"        Reduce the symptoms of depression",
"       </li>",
"       <li>",
"        Relieve anxiety",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Each of the antidepressants works in a different way. But in general, they all change the chemistry of the brain (",
"      <a class=\"graphic graphic_figure graphicRef60356 \" href=\"UTD.htm?39/44/40640\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736516\">",
"      <span class=\"h1\">",
"       Which medicine might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will decide which medicine is best for you. He or she might ask if any of your family members have had good luck with a particular antidepressant. If so, that might be a good place for you to start. The section at the end lists the most common antidepressant choices. Most people take just 1 antidepressant, but some people take 2 or 3 of the medicines together.",
"     </p>",
"     <p>",
"      The first medicine you try might not help enough. If that happens, tell your doctor or nurse, and don&rsquo;t give up. People sometimes need to try a few different medicines or combinations of medicines before they find the treatment that works for them.",
"     </p>",
"     <p>",
"      The section at the end includes some basic information on the main medicines used in depression. If you would like more detailed information, including information on the side effects caused by specific medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736523\">",
"      <span class=\"h1\">",
"       How long before I feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most antidepressants start to help within 2 weeks of when you start taking them. But it usually takes 4 to 6 weeks before you get the full effect. If you don&rsquo;t feel any better after 2 to 4 weeks, ask your doctor or nurse what you can do. He or she might increase your dose, prescribe a second medicine, or offer another solution.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736530\">",
"      <span class=\"h1\">",
"       What if I have side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have minor side effects when you start taking an antidepressant, try staying on the medicine for a few weeks. Minor side effects often go away after your body gets used to the new medicine. If side effects do not go away or worry you, mention your problems to your doctor or nurse. He or she might have suggestions for how to reduce or deal with your side effects.",
"     </p>",
"     <p>",
"      Each of the medicines is different, but in general, side effects from antidepressants can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling jittery or restless",
"       </li>",
"       <li>",
"        Having trouble sleeping",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"       <li>",
"        Nausea or diarrhea",
"       </li>",
"       <li>",
"        Problems with sex",
"       </li>",
"       <li>",
"        Weight gain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      This table lists the generic and US brand names of several antidepressants and how likely each medicine is to cause certain side effects (",
"      <a class=\"graphic graphic_table graphicRef81374 \" href=\"UTD.htm?42/3/43069\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736537\">",
"      <span class=\"h1\">",
"       How long do I keep taking the medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people stay on antidepressants for at least 6 to 9 months. If you have severe depression, it might make sense to stay on your antidepressant for a year or more. People with severe depression who recover and then go off their medicines often get depressed again.",
"     </p>",
"     <p>",
"      If and when you do go off your medicine, do it with the help of your doctor or nurse. You will need to slowly decrease your dose over a few weeks. Stopping antidepressants all of a sudden can cause uncomfortable symptoms.",
"     </p>",
"     <p>",
"      Medicines to treat depression:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         SSRIs (selective serotonin reuptake inhibitors) &mdash;",
"        </strong>",
"        SSRIs are usually the first medicines doctors prescribe when they are treating someone with depression. SSRIs often work well, are safe, and have fewer side effects than many of the other medicines. Some examples of SSRIs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?11/49/12054?source=see_link\">",
"         citalopram",
"        </a>",
"        (brand name: Celexa&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?29/58/30630?source=see_link\">",
"         fluoxetine",
"        </a>",
"        (brand name: Prozac&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23222?source=see_link\">",
"         sertraline",
"        </a>",
"        (brand name: Zoloft&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         SNRIs (selective norepinephrine reuptake inhibitors)",
"        </strong>",
"        &mdash; SNRIs work in a similar way to SSRIs, but they also have other effects. Doctors sometimes suggest these medicines when SSRIs do not help enough. Some examples of SNRIs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/42/9894?source=see_link\">",
"         duloxetine",
"        </a>",
"        (brand name: Cymbalta&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=see_link\">",
"         venlafaxine",
"        </a>",
"        (brand name: Effexor&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         Other antidepressants",
"        </strong>",
"        &mdash;",
"        <strong>",
"        </strong>",
"        Other antidepressants include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?17/7/17526?source=see_link\">",
"         bupropion",
"        </a>",
"        (brand name: Wellbutrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?32/45/33493?source=see_link\">",
"         mirtazapine",
"        </a>",
"        (brand name: Remeron&reg;). These medicines do not tend to cause sex-related side effects, so doctors sometimes give them to people who have those side effects with other antidepressants. Bupropion does not cause weight gain, and it can be especially helpful to people who lack energy, but it can cause jitteriness. Mirtazapine increases appetite and can cause weight gain, so doctors sometimes give it to people with low appetite. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         TCAs (tricyclic and tetracyclic antidepressants)",
"        </strong>",
"        &mdash; TCAs are not used as much as SSRIs and SNRIs, because TCAs can cause more side effects, such as constipation and drowsiness. In addition, TCAs can disrupt the heart&rsquo;s rhythm and cause other serious problems. In elderly people, these medicines can also cause confusion and memory problems. Even so, TCAs can help some people with depression, especially if they do not get better with SSRIs or SNRIs. Some examples of TCAs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?25/22/25957?source=see_link\">",
"         nortriptyline",
"        </a>",
"        (brand name: Pamelor&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?26/24/27013?source=see_link\">",
"         desipramine",
"        </a>",
"        (brand name: Norpramin&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         MAOIs (monoamine oxidase inhibitors)",
"        </strong>",
"        &mdash; MAOIs are not used very often because they can cause a lot of side effects, and because people who take them must avoid certain foods and medicines. Still, MAOIs can help people who have depression along with other problems or who do not get better with other medicines. Some examples of MAOIs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/42/39589?source=see_link\">",
"         tranylcypromine",
"        </a>",
"        (brand name: Parnate&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?31/35/32309?source=see_link\">",
"         phenelzine",
"        </a>",
"        (brand name: Nardil&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21736619\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=see_link\">",
"       Patient information: Generalized anxiety disorder (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/482?source=see_link\">",
"       Patient information: Serotonin syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       Patient information: Bipolar disorder (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       Patient information: Depression in adolescents (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       Patient information: Depression treatment options for adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/6/24675?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16163 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24675=[""].join("\n");
var outline_f24_6_24675=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736509\">",
"      What do medicines for depression do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736516\">",
"      Which medicine might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736523\">",
"      How long before I feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736530\">",
"      What if I have side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736537\">",
"      How long do I keep taking the medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21736619\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16163\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/44/40640\">",
"      Mood disorders caused by problems in the brain",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?42/3/43069\">",
"       Chance of side effects with certain antidepressant medicines",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=related_link\">",
"      Patient information: Generalized anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/482?source=related_link\">",
"      Patient information: Serotonin syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24676="Rilonacept: Patient drug information";
var content_f24_6_24676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rilonacept: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     see \"Rilonacept: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/9/14484?source=see_link\">",
"     see \"Rilonacept: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5726811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arcalyst&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691800",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cryopyrin-associated periodic syndromes (CAPS).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rilonacept or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor. You may have a chance of a very bad infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not shake.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12055 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24676=[""].join("\n");
var outline_f24_6_24676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5726811\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017820\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017822\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017821\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017826\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017827\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017829\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017824\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017825\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017830\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017831\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=related_link\">",
"      Rilonacept: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/9/14484?source=related_link\">",
"      Rilonacept: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24677="Methocarbamol: Drug information";
var content_f24_6_24677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methocarbamol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/1/23572?source=see_link\">",
"    see \"Methocarbamol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/59/40884?source=see_link\">",
"    see \"Methocarbamol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Robaxin&reg;;",
"     </li>",
"     <li>",
"      Robaxin&reg;-750",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Robaxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skeletal Muscle Relaxant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Muscle spasm:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1.5 g 4 times/day for 2-3 days (up to 8 g/day may be given in severe conditions), then decrease to 4-4.5 g/day in 3-6 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: Initial: 1 g; may repeat every 8 hours if oral administration not possible; maximum dose: 3 g/day for no more than 3 consecutive days. If condition persists, may repeat course of therapy after a drug-free interval of 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tetanus:",
"     </b>",
"     I.V.: Initial dose: 1-2 g by direct I.V. injection, which may be followed by an additional 1-2 g by infusion (maximum initial dose: 3 g total); may repeat initial dose every 6 hours until NG tube or oral therapy possible; total oral daily dose of up to 24 g may be needed; injection should not be used for more than 3 consecutive days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/59/40884?source=see_link\">",
"      see \"Methocarbamol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tetanus",
"     </b>",
"     (recommended",
"     <b>",
"      only",
"     </b>",
"     for use in tetanus): I.V.: 15 mg/kg/dose or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose, may repeat every 6 hours if needed; maximum dose: 1.8 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Muscle spasm:",
"     </b>",
"     Oral: Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F194403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of the parenteral formulation is contraindicated in patients with renal dysfunction due to the presence of polyethylene glycol.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F194404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific dosing guidelines are not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robaxin&reg;: 100 mg/mL (10 mL) [contains natural rubber/natural latex in packaging, polyethylene glycol 300]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robaxin&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robaxin&reg;-750: 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F194378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution for injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: A maximum of 5 mL can be administered into each gluteal region.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Maximum rate: 3 mL/minute; may be administered undiluted or diluted. Monitor closely for extravasation. Administer I.V. while in recumbent position. Maintain position for at least 10-15 minutes following infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: May be crushed and mixed with food or liquid if needed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of muscle spasm associated with acute painful musculoskeletal conditions (eg, tetanus)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methocarbamol may be confused with mephobarbital",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Robaxin&reg; may be confused with ribavirin, Skelaxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Robaxin [U.S., Canada, Great Britain, Greece, Spain] may be confused with Rubex brand name for ascorbic acid [Ireland]; doxorubicin [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, flushing, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, confusion, coordination impaired (mild), dizziness, drowsiness, fever, headache, insomnia, lightheadedness, sedation, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema,  pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, metallic taste, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions including anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methocarbamol or any component of the formulation; renal impairment (injection formulation)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Plasma protein binding and clearance are decreased and the half-life is increased in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use of I.V. formulation is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use injection with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Muscle relaxants are poorly tolerated by the elderly due to potent anticholinergic effects, sedation, and risk of fracture. Efficacy is questionable at dosages tolerated by elderly patients; avoid use (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: I.V. formulation: Recommended only for the treatment of tetanus in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Contraindicated in renal impairment. Contains polyethylene glycol. Rate of injection should not exceed 3 mL/minute; solution is hypertonic; avoid extravasation. Vial stopper contains latex.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridostigmine: Methocarbamol may diminish the therapeutic effect of Pyridostigmine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F194394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. The manufacturer notes that fetal and congenital abnormalities have been rarely reported following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Robaxin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $42.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methocarbamol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $41.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $49.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Robaxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $170.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13361213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor closely for extravasation (I.V. administration).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bolaxin (TW);",
"     </li>",
"     <li>",
"      Carbaflex (HN, NI, SV);",
"     </li>",
"     <li>",
"      Carbamol (KP);",
"     </li>",
"     <li>",
"      Lumirelax (FR);",
"     </li>",
"     <li>",
"      Manobaxine (TH);",
"     </li>",
"     <li>",
"      Methocarbamol (PL);",
"     </li>",
"     <li>",
"      Metocamol (KP);",
"     </li>",
"     <li>",
"      Miowas (ES, IT);",
"     </li>",
"     <li>",
"      Musxan (TH);",
"     </li>",
"     <li>",
"      Myomethol (HK);",
"     </li>",
"     <li>",
"      Myorexin Inj (KP);",
"     </li>",
"     <li>",
"      New-Rexan (KP);",
"     </li>",
"     <li>",
"      Ortoton (DE);",
"     </li>",
"     <li>",
"      Rebamol (TW);",
"     </li>",
"     <li>",
"      Rexivin (MX);",
"     </li>",
"     <li>",
"      Robaxin (AE, BB, BH, BM, BS, BZ, CH, CO, CY, EG, ES, FI, GY, IL, IQ, IR, JM, JO, KP, KW, LB, LY, NL, OM, QA, SA, SR, SY, TT, YE, ZA);",
"     </li>",
"     <li>",
"      Robaxin-750 (GB);",
"     </li>",
"     <li>",
"      Robinax (IN);",
"     </li>",
"     <li>",
"      Sinaxar (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes skeletal muscle relaxation by general CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Muscle relaxation: Oral: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 46% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via dealkylation and hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24677/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9628 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24677=[""].join("\n");
var outline_f24_6_24677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194398\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194429\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194401\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194416\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194403\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194404\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194375\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194360\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194378\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194377\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194436\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194427\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194381\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194364\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194369\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194394\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194372\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194384\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194408\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194383\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361213\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194385\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194363\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194380\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/1/23572?source=related_link\">",
"      Methocarbamol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/59/40884?source=related_link\">",
"      Methocarbamol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24678="Albendazole: Drug information";
var content_f24_6_24678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Albendazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/36/31300?source=see_link\">",
"    see \"Albendazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/1/10261?source=see_link\">",
"    see \"Albendazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Albenza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anthelmintic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Neurocysticercosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;60 kg: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day) for 8-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;60 kg: 800 mg/day in 2 divided doses for 8-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Give concurrent anticonvulsant and steroid therapy during first week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hydatid:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;60 kg: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;60 kg: 800 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Administer dose for three 28-day cycles with a 14-day drug-free interval in between each cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Ancylostoma caninum",
"      </i>",
"      ,",
"      <i>",
"       Ascaris lumbricoides",
"      </i>",
"      (roundworm),",
"      <i>",
"       Ancylostoma duodenale",
"      </i>",
"      (hookworm), and",
"      <i>",
"       Necator americanus",
"      </i>",
"      (hookworm) (unlabeled use):",
"     </b>",
"     Oral: 400 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Clonorchis sinensis",
"      </i>",
"      (Chinese liver fluke) (unlabeled use):",
"     </b>",
"     Oral: 10 mg/kg/day for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Cutaneous larva migrans (unlabeled use):",
"     </b>",
"     Oral: 400 mg once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Enterobius vermicularis",
"      </i>",
"      (pinworm) (unlabeled use):",
"     </b>",
"     Oral: 400 mg as a single dose; repeat in 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Giardia duodenalis",
"      </i>",
"      (giardiasis) (unlabeled use):",
"     </b>",
"     Oral: 400 mg once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Gnathostoma spinigerum",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Gongylonemiasis (unlabeled use):",
"     </b>",
"     Oral: 400 mg once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mansonella perstans",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Oesophagostomum bifurcum",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     Oral: 400 mg as a single dose (Ziem, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Trichinella spiralis",
"      </i>",
"      (Trichinellosis) (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 8-14 days plus steroids for severe symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Visceral larva migrans (toxocariasis) (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Cysticercus cellulosae",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 8-30 days; may be repeated as necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Disseminated microsporidiosis (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Echinococcus granulosus",
"      </i>",
"      (tapeworm) (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 1-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Intestinal microsporidiosis (",
"      <i>",
"       E. intestinalis",
"      </i>",
"      ) (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ocular microsporidiosis (unlabeled use):",
"     </b>",
"     Oral: 800 mg/day in 2 divided doses, in combination with fumagillin",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F130850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/1/10261?source=see_link\">",
"      see \"Albendazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neurocysticercosis:",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydatid:",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Cysticercus cellulosae",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     Oral: 15 mg/kg/day (maximum: 800 mg/day) in 2 divided doses for 8-30 days; may be repeated as necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Echinococcus granulosus",
"      </i>",
"      (tapeworm) (unlabeled use):",
"     </b>",
"     Oral: 15 mg/kg/day (maximum: 800 mg) divided twice daily for 1-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Giardia duodenalis",
"      </i>",
"      (giardiasis) (unlabeled use):",
"     </b>",
"     Oral: 10 mg/kg/day for 5 days (Yereli, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Microsporidiosis (other than",
"      <i>",
"       Enterocytozoon bienuesi  or",
"      </i>",
"      or",
"      <i>",
"       V. corneae",
"      </i>",
"      ), disseminated or intestinal infection (HIV-positive, unlabeled use):",
"     </b>",
"     Oral: Infants and Children: 15 mg/kg/day (maximum: 800 mg/day) in 2 divided doses continued until immune reconstitution after HAART initiation (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      For the following unlabeled uses, refer to adult dosing:",
"     </b>",
"     <i>",
"      Ancylostoma caninum",
"     </i>",
"     ,",
"     <i>",
"      Ascaris lumbricoides",
"     </i>",
"     (roundworm),",
"     <i>",
"      Ancylostoma duodenale",
"     </i>",
"     (hookworm),",
"     <i>",
"      Clonorchis sinensis",
"     </i>",
"     , (Chinese liver fluke), cutaneous larva migrans,",
"     <i>",
"      Enterobius vermicularis",
"     </i>",
"     (pinworm),",
"     <i>",
"      Gnathostoma spinigerum",
"     </i>",
"     , gongylonemiasis,",
"     <i>",
"      Mansonella perstans",
"     </i>",
"     ,",
"     <i>",
"      Necator americanus",
"     </i>",
"     (hookworm),",
"     <i>",
"      Oesophagostomum bifurcum",
"     </i>",
"     ,",
"     <i>",
"      Trichinella spiralis",
"     </i>",
"     (Trichinellosis), visceral larva migrans (toxocariasis)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer's labeling (has not been studied). However, the need for adjustment not likely since albendazole is primarily eliminated by hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, patients with underlying liver disease may be more at risk for adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albenza&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered with a high-fat meal. Administer anticonvulsant and steroid therapy during first week of neurocysticercosis therapy. If patients have difficulty swallowing, tablets may be crushed or chewed, then swallowed with a drink of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of parenchymal neurocysticercosis caused by",
"     <i>",
"      Taenia solium",
"     </i>",
"     and cystic hydatid disease of the liver, lung, and peritoneum caused by",
"     <i>",
"      Echinococcus granulosus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F130863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Albendazole has activity against",
"     <i>",
"      Ascaris lumbricoides",
"     </i>",
"     (roundworm);",
"     <i>",
"      Ancylostoma caninum",
"     </i>",
"     ;",
"     <i>",
"      Ancylostoma duodenale",
"     </i>",
"     and",
"     <i>",
"      Necator americanus",
"     </i>",
"     (hookworms); cutaneous larva migrans;",
"     <i>",
"      Enterobius vermicularis",
"     </i>",
"     (pinworm);",
"     <i>",
"      Giardia duodenalis",
"     </i>",
"     (giardiasis);",
"     <i>",
"      Gnathostoma spinigerum",
"     </i>",
"     ;",
"     <i>",
"      Gongylonema",
"     </i>",
"     sp;",
"     <i>",
"      Mansonella perstans",
"     </i>",
"     (filariasis);",
"     <i>",
"      Oesophagostomum bifurcum",
"     </i>",
"     ;",
"     <i>",
"      Opisthorchis sinensis",
"     </i>",
"     (liver fluke);",
"     <i>",
"      Trichinella spiralis",
"     </i>",
"     (Trichinellosis); visceral larva migrans (toxocariasis); activity has also been shown against the liver fluke",
"     <i>",
"      Clonorchis sinensis",
"     </i>",
"     ,",
"     <i>",
"      Giardia lamblia",
"     </i>",
"     ,",
"     <i>",
"      Cysticercus cellulosae",
"     </i>",
"     , and",
"     <i>",
"      Echinococcus multilocularis",
"     </i>",
"     . Albendazole has also been used for the treatment of intestinal microsporidiosis (",
"     <i>",
"      Encephalitozoon intestinalis",
"     </i>",
"     ), disseminated microsporidiosis (",
"     <i>",
"      E. hellem",
"     </i>",
"     ,",
"     <i>",
"      E. cuniculi",
"     </i>",
"     ,",
"     <i>",
"      E. intestinalis",
"     </i>",
"     ,",
"     <i>",
"      Pleistophora",
"     </i>",
"     sp,",
"     <i>",
"      Trachipleistophora",
"     </i>",
"     sp,",
"     <i>",
"      Brachiola vesicularum",
"     </i>",
"     ), and ocular microsporidiosis (",
"     <i>",
"      E. hellem",
"     </i>",
"     ,",
"     <i>",
"      E. cuniculi",
"     </i>",
"     ,",
"     <i>",
"      Vittaforma corneae",
"     </i>",
"     ).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3195081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Albenza&reg; may be confused with Aplenzin&trade;, Relenza&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Albenza [U.S.] may be confused with Avanza brand name for mirtazapine [Australia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (11% neurocysticercosis; 1% hydatid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs increased (16% hydatid; &lt;1% neurocysticercosis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Intracranial pressure increased (&le;2%), dizziness (&le;1%), fever (&le;1%), vertigo (&le;1%), meningeal signs (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (&le;6%), nausea/vomiting (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening symptoms): Acute liver failure, acute renal failure, aplastic anemia, agranulocytosis, erythema multiforme, granulocytopenia, hepatitis, hypersensitivity reaction, leukopenia, neutropenia, pancytopenia, rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to albendazole, benzimidazoles, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, and pancytopenia have occurred leading to fatalities (rare); use with caution in patients with hepatic impairment (more susceptible to hematologic toxicity).  Discontinue therapy in all patients who develop clinically significant decreases in blood cell counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transaminase elevations: Reversible elevations in hepatic enzymes have been reported. Patients with abnormal LFTs and hepatic echinococcosis are at an increased risk of hepatotoxicity.  Discontinue therapy if LFT elevations are &gt;2 times the upper limit of normal; may consider restarting treatment (with frequent monitoring of LFTs) when hepatic enzymes return to pretreatment values.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurocysticercosis: Appropriate use: Corticosteroids should be administered before or upon initiation of albendazole therapy to minimize inflammatory reactions and prevent cerebral hypertension. Anticonvulsant therapy should be used concurrently during the first week of therapy to prevent seizures. These measures are important to minimize neurological symptoms which may result from uncovering of pre-existing neurocysticercosis when using albendazole to treat other conditions. If retinal lesions exist, weigh risk of further retinal damage due to albendazole-induced changes to the retinal lesion vs benefit of disease treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F130860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase serum concentrations of the active metabolite(s) of Albendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F130829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Albendazole serum levels may be increased if taken with a fatty meal (increases the oral bioavailability by up to 5 times). Management: Should be administered with a high-fat meal (peanuts or ice cream).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Albendazole has been shown to be teratogenic in laboratory animals and should not be used during pregnancy, if at all possible. Women should be advised to avoid pregnancy for at least 1 month following therapy. Discontinue if pregnancy occurs during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F130821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with a high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F130819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Albenza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (2): $86.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor fecal specimens for ova and parasites for 3 weeks after treatment; if positive, retreat; LFTs and CBC with differential at start of each 28-day cycle and every 2 weeks during therapy (more frequent monitoring for patients with liver disease); ophthalmic exam (patients with neurocysticercosis); pregnancy test",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      ABZ (IN);",
"     </li>",
"     <li>",
"      Acure (PK);",
"     </li>",
"     <li>",
"      Albatel (TH);",
"     </li>",
"     <li>",
"      Alben (BR);",
"     </li>",
"     <li>",
"      Alben-VC (TH);",
"     </li>",
"     <li>",
"      Albentel (PE);",
"     </li>",
"     <li>",
"      Albenzol (EC);",
"     </li>",
"     <li>",
"      Albex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Albezole (IN);",
"     </li>",
"     <li>",
"      Alfuca (TH);",
"     </li>",
"     <li>",
"      Almex (MY);",
"     </li>",
"     <li>",
"      Alminth (IN);",
"     </li>",
"     <li>",
"      Alzental (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Alzol (TH);",
"     </li>",
"     <li>",
"      Andazol (TR);",
"     </li>",
"     <li>",
"      Ascarol (EC);",
"     </li>",
"     <li>",
"      Bendex-400 (ZA);",
"     </li>",
"     <li>",
"      Benzol (PH);",
"     </li>",
"     <li>",
"      Bruzol (MX);",
"     </li>",
"     <li>",
"      CB-400 (TH);",
"     </li>",
"     <li>",
"      Ceprazol (CN);",
"     </li>",
"     <li>",
"      Ciclopar (CO);",
"     </li>",
"     <li>",
"      Dalben (HR);",
"     </li>",
"     <li>",
"      Digezanol (MX);",
"     </li>",
"     <li>",
"      Emanthal (IN);",
"     </li>",
"     <li>",
"      Eskasole (MX);",
"     </li>",
"     <li>",
"      Eskazole (AT, AU, DE, ES, GB, IL, JP, NL, NZ);",
"     </li>",
"     <li>",
"      Fintel (PE);",
"     </li>",
"     <li>",
"      Gascop (MX);",
"     </li>",
"     <li>",
"      Helmiben (UY);",
"     </li>",
"     <li>",
"      Helmidazole (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Hyemex (PH);",
"     </li>",
"     <li>",
"      Labenda (TH);",
"     </li>",
"     <li>",
"      Lomsin (MX);",
"     </li>",
"     <li>",
"      Lurdex (MX);",
"     </li>",
"     <li>",
"      Mebenix (BR);",
"     </li>",
"     <li>",
"      Mesin-C (MY);",
"     </li>",
"     <li>",
"      Nemozole (IN);",
"     </li>",
"     <li>",
"      Pantex (PY);",
"     </li>",
"     <li>",
"      Paranthil (ZA);",
"     </li>",
"     <li>",
"      Rotopar (EC);",
"     </li>",
"     <li>",
"      Sioban (IN);",
"     </li>",
"     <li>",
"      Thelban (MY);",
"     </li>",
"     <li>",
"      Tilminth (PH);",
"     </li>",
"     <li>",
"      Valbazen Vet (NO);",
"     </li>",
"     <li>",
"      Vastus (AR);",
"     </li>",
"     <li>",
"      Vemizol (MY);",
"     </li>",
"     <li>",
"      Vermin Plus (MX);",
"     </li>",
"     <li>",
"      Vetoben (TH);",
"     </li>",
"     <li>",
"      Zeben (TH);",
"     </li>",
"     <li>",
"      Zela (TH);",
"     </li>",
"     <li>",
"      Zendal (MY);",
"     </li>",
"     <li>",
"      Zentel (AE, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, DO, EC, EG, ET, FR, GH, GM, GN, GR, GT, GY, HN, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, OM, PA, PE, PH, PL, PR, PT, QA, SA, SC, SD, SG, SL, SN, SR, SV, SY, TH, TN, TT, TZ, UG, VE, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active metabolite, albendazole sulfoxide, causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired, and desecratory substances accumulate intracellulary. ATP production decreases causing energy depletion, immobilization, and worm death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor; may increase up to 5 times when administered with a fatty meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Well inside hydatid cysts and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; extensive first-pass effect; pathways include rapid sulfoxidation to active metabolite (albendazole sulfoxide [major]), hydrolysis, and oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as active metabolite); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bethony J, Brooker S, Albonico M, et al, &ldquo;Soil-Transmitted Helminth Infections: Ascariasis, Trichuriasis, and Hookworm,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9521):1521-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/16679166/pubmed\" id=\"16679166\" target=\"_blank\">",
"        16679166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Del Brutto OH, Roos KL, Coffey  CS, et al, &ldquo;Meta-Analysis: Cysticidal Drugs for Neurocysticercosis: Albendazole and Praziquantel,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2006, 145(1):43-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/16818928/pubmed\" id=\"16818928\" target=\"_blank\">",
"        16818928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Silva N, Guyatt H, and Bundy D, &ldquo;Anthelmintics. A Comparative Review of Their Clinical Pharmacology,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(5):769-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/9129865/pubmed\" id=\"9129865\" target=\"_blank\">",
"        9129865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2007, 5(suppl):e1-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia HH, Gilman RH, Horton J, et al, &ldquo;Albendazole therapy for neurocysticercosis: A Prospective Double-Blind Trial Comparing 7 Versus 14 Days of Treatment,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 48(5):1421-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/9153484/pubmed\" id=\"9153484\" target=\"_blank\">",
"        9153484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia HH, Pretell EJ, Gilman RH, &ldquo;A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(3):249-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/14724304/pubmed\" id=\"14724304\" target=\"_blank\">",
"        14724304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawk MW, Shahlaie K, Kim KD, and Theis JH, &ldquo;Neurocysticercosis: A Review,&rdquo;",
"      <i>",
"       Surg Neurol",
"      </i>",
"      , 2005, 63(2):123-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/15680651/pubmed\" id=\"15680651\" target=\"_blank\">",
"        15680651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smego, RA, Bhatti S, Khaliq AA, et al, &ldquo;Percutaneous Aspiration-Injection-Reaspiration Drainage Plus Albendazole or Mebendazole for Hepatic Cystic Echinococcosis: A Meta-Analysis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 37(8):1073-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/14523772/pubmed\" id=\"14523772\" target=\"_blank\">",
"        14523772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson ME, Lorente CA, Allen JE, et al, &ldquo;Gongylonema Infection of the Mouth in a Resident of Cambridge, Massachusetts,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2001, 32(9):1378-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/11303277/pubmed\" id=\"11303277\" target=\"_blank\">",
"        11303277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yereli K, Balciolu IC, Ertan P, et al, \"Albendazole as an Alternative Therapeutic Agent for Childhood Giardiasis in Turkey,\"",
"      <i>",
"       Clin Microbiol Infect",
"      </i>",
"      , 2004, 10(6):527-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/15191380/pubmed\" id=\"15191380\" target=\"_blank\">",
"        15191380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ziem JB, Kettenis IM, Bayita A, et al, \"The Short-Term Impact of Albendazole Treatment on",
"      <i>",
"       Oesophagostomum bifurcum",
"      </i>",
"      and Hookworm Infections in Northern Ghana,\"",
"      <i>",
"       Ann Trop Med Parasitol",
"      </i>",
"      , 2004, 98(4):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/6/24678/abstract-text/15228719/pubmed\" id=\"15228719\" target=\"_blank\">",
"        15228719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9371 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24678=[""].join("\n");
var outline_f24_6_24678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130833\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130867\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130835\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130850\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130836\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671330\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671331\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130814\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130813\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130863\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195081\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130865\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130817\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130803\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130860\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130807\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130829\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130808\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130820\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130839\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130821\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130819\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130810\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130822\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130802\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130816\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9371|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/36/31300?source=related_link\">",
"      Albendazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/1/10261?source=related_link\">",
"      Albendazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24679="Medicare";
var content_f24_6_24679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medicare",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24679/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24679/contributors\">",
"     Robert Baldor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24679/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24679/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/6/24679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicare is a United States publicly funded federal health insurance plan for the elderly and disabled that covers about 45 million Americans. People contribute to Medicare by payroll taxes paid during their years of employment. These funds are held in the Hospital Insurance Trust fund and are administered by the Centers for Medicare and Medicaid Services (CMS).",
"   </p>",
"   <p>",
"    The following groups are eligible for Medicare benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all individuals older than 65 years of age (excluded are those who have not contributed to the Medicare program during their working years)",
"     </li>",
"     <li>",
"      Those younger than 65 who are receiving social security disability payments",
"     </li>",
"     <li>",
"      People requiring dialysis regardless of their age via the end-stage renal disease (ESRD) program",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medicare consists of four parts (A,B,C,D): Part A primarily pays for inpatient services; Part B covers outpatient services; Part C (\"Medicare + Choice\", renamed \"Medicare Advantage\" in 2006), and Part D, a pharmacy benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC COVERAGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Part A (the hospital insurance program)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all people receiving social security benefits are eligible for Part A coverage through Medicare. There is no enrollment fee for most recipients because they or their spouses have 40 or more quarters of Medicare-covered employment. However, those with 30 to 39 quarters of coverage pay a monthly premium of $248, and those with less than 30 quarters may obtain Part A coverage by paying a monthly premium of up to $451 in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are associated costs including annual deductibles and co- payments. The deductible for inpatient hospital services varies annually, but for the year 2012 it is set at $1156 per \"benefit period.\" A benefit period refers to a specific hospitalization, and lasts 60 days after discharge from the hospital or skilled nursing facility (SNF). Patients who are readmitted within this time frame would not have to pay the deductible again [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/1\">",
"     1",
"    </a>",
"    ]. Medicare pays coinsurance amounts for hospital stays beyond 60 days.",
"   </p>",
"   <p>",
"    In summary, in 2012 patients pay:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A total of $1156 for a hospital stay of 1 to 60 days",
"     </li>",
"     <li>",
"      $289 per day for days 61 to 90 of a hospital stay",
"     </li>",
"     <li>",
"      $578 per day for days 90 to 150 of a hospital stay (Lifetime Reserve Days; up to 60 days over a lifetime)",
"     </li>",
"     <li>",
"      All costs for each day beyond 150 days",
"     </li>",
"     <li>",
"      Costs for inpatient mental health care up to 190 days in a lifetime",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to hospital care, Medicare Part A also covers some skilled nursing facility (SNF), home health, and hospice care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link&amp;anchor=H691082#H691082\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\", section on 'The US Medicare hospice benefit'",
"    </a>",
"    .) Medicare will cover the first 20 days of SNF care entirely, but after that, in 2012, the beneficiary must pay a daily $144.50 co- payment for the next 80 days. Total payment is limited to 100 days per benefit period, after which the beneficiary is responsible for all costs. Medicare does not cover long term care or custodial care. However, it does cover hospice care for up to two 90-day periods, followed by an unlimited number of 60-day periods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Part B (the medical insurance program)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional medical insurance is available to people receiving social security to cover basic outpatient care, but it must be purchased by the individual. About 95 percent of Medicare recipients are enrolled in this optional plan, which is purchased via a monthly premium withheld from the individual's social security check. In 2007, the premium was changed to be based on income. For 2012, the monthly premium is set at $99.90 for those whose annual income is less than $85,000 ($170,000 if married and filing a joint tax return). Premiums increase above that level (",
"    <a class=\"graphic graphic_table graphicRef52627 \" href=\"UTD.htm?17/21/17755\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additionally, there is an annual deductible ($140.00 in 2012), and the patient is responsible for co-payments of 20 percent of most other medical services after meeting the deductible amount.",
"   </p>",
"   <p>",
"    Part B covers physician services, outpatient hospital care, ambulatory surgical services, x-rays, durable medical equipment, laboratory, and home health care. Physical therapy, occupational therapy, and therapy for speech-language pathology are also covered. Outpatient mental health services are covered but with a 45 percent co-pay in 2011, which decreases to 20 percent in 2014 as a component of the 2010 Patient Protection and Affordable Care Act (PPACA) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PPACA also expanded coverage for preventive services such as mammograms, pap smears, and flu shots along with free preventive care visits as outlined below. Many services recommended by the United States Preventive Services Task Force (USPSTF) are fully covered and free for beneficiaries [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/3\">",
"     3",
"    </a>",
"    ]. The list of covered preventive services has been expanded (",
"    <a class=\"graphic graphic_table graphicRef81816 \" href=\"UTD.htm?12/17/12573\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15408229\">",
"    <span class=\"h3\">",
"     Preventive care visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Medicare Modernization Act (MMA) of 2003 provides for a no-cost &ldquo;Welcome to Medicare&rdquo; physical exam for Part B beneficiaries who are within six months of the effective date of their coverage. The visit focuses on identifying medical risk factors along with requiring patient education, counseling, and referral for Medicare-covered preventive services. Additionally, an &rdquo;Annual Wellness Visit&rdquo; with a participating doctor is also covered at no cost to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/4\">",
"     4",
"    </a>",
"    ]. However, in order to bill for these visit, the physician must provide and document specific essential elements for the visit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The &ldquo;Welcome to Medicare&rdquo; exam has seven required elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comprehensive medical, family, and social history",
"     </li>",
"     <li>",
"      Review of risk factors for depression (using an available standardized screening tests designed for this purpose)",
"     </li>",
"     <li>",
"      Review of functional ability and level of safety (including evaluating hearing, activities of daily living, functional ability, and level of safety)",
"     </li>",
"     <li>",
"      A focused physical exam (height, weight, BMI, blood pressure, and visual acuity are the only required components)",
"     </li>",
"     <li>",
"      Performance and interpretation of an electrocardiogram (ECG, results need to be incorporated into the medical record, whether completed in the office or referred)",
"     </li>",
"     <li>",
"      Education, counseling, and referral to address any pertinent health issues identified during this exam",
"     </li>",
"     <li>",
"      Education, counseling, referral, and providing a written checklist regarding separate preventive care services covered by Medicare Part B (there are 11 preventive services authorized under Medicare Part B)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subsequent Annual Wellness Visits (AWV) are divided into whether it is the initial AWV or subsequent AWV. The initial AWV includes several elements as noted above for the Welcome to Medicare Exam, although an ECG is not required; however a list of current providers and suppliers who are regularly involved in providing medical care to the patient must be recorded. &ldquo;Voluntary advance care planning&rdquo; is recommended with preparation of an advance directive. Subsequent AWV require reviewing and updating the information from the previous AWV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254562329\">",
"    <span class=\"h2\">",
"     Part C (Medicare Advantage)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicare offers enrollees options for care outside of the traditional \"fee-for-service\" medical delivery system and assistance with the cost of prescription drugs. The intent of this program is to provide enrollees with expanded options for accessing health care. This program allows patients to opt out of the traditional \"fee-for-service\" insurance plan and enroll in a managed care plan such as a Health Maintenance Organization (HMO) or a Preferred Provider Organization (PPO). Special Needs Plans (SNPs) are also included; these plans serve patients who live in nursing homes or require significant home services due to a chronic illness.",
"   </p>",
"   <p>",
"    This option combines Part A and B coverage and many plans provide services beyond traditional \"fee-for-service\" Medicare, such as eyeglasses, dentures, and prescription drugs. However, HMOs typically restrict patient options for choosing their doctors and require prior approval for visits to other health providers and for diagnostic tests and other services. Beneficiaries continue to pay monthly Medicare B premiums and may incur additional costs, as private insurance companies set their own fees [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regional preferred provider organization plans offer patients a list of preferred providers. Patient fees are lower, and the need for prior approval is obviated if patients seek care with the providers who have contracted with the PPO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254562397\">",
"    <span class=\"h2\">",
"     Part D (Prescription drug coverage)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This prescription drug benefit was implemented in 2006 as a component of the Medicare Modernization Act of 2003. Prescription drug plans are provided by private insurance companies and other private companies working with Medicare. Prescription drug coverage is provided by stand-alone prescription drug plans or as part of a Medicare Advantage plan. Plans are available nationwide and cover brand name and generic drugs. The prescription drug benefit requires an additional monthly premium and prescription co-payments that vary depending on the plan that is chosen. The national average monthly premium for the basic Medicare drug benefit in 2012 is $31.08 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/1\">",
"     1",
"    </a>",
"    ]. Some prescription drug plans do not charge a premium.",
"   </p>",
"   <p>",
"    Drug plans vary in what drugs are covered, co-payments charged, and which pharmacies can be used. Medicare has set a standard level of coverage, which all drug plans have to provide. For example, all formularies must include at least two drugs from each drug category and class and be comparable to the United States Pharmacopoeia (USP) model to ensure sufficient breadth of categories and classes. Formularies must include all available medications for six special drug classes: antineoplastics,",
"    <span class=\"nowrap\">",
"     anti-HIV/AIDS",
"    </span>",
"    drugs, immunosuppressants, antipsychotics, antidepressants, and anticonvulsants. Finally, all plans must have an appeals and exceptions process if a non-formulary drug needs to be provided.",
"   </p>",
"   <p>",
"    An average income Medicare recipient enrolled in a prescription drug plan in 2012 would expect to pay for the initial $320 of drug expenses (annual deductible) and then 25 percent of drug costs up to an initial coverage limit of $2930 (plus the deductible costs) annually. After this point there is a gap in coverage known as the &ldquo;doughnut hole,&rdquo; in which recipients must pay all costs until they have spent a total of $4700 out-of-pocket for their medications.",
"   </p>",
"   <p>",
"    The 2010 PPACA health reform act gradually decreases the costs of medications Part D enrollees pay for prescriptions when they reach the coverage gap. In 2012, those who reach the gap will receive a 50 percent discount on covered brand-name prescription drugs and will pay 86 percent of the plan&rsquo;s cost for covered generic drugs. Both the patient&rsquo;s drug expenditures and the 50 percent brand-name drug subsidy paid by its manufacturer will count toward total out-of-pocket expenditures, helping the patient reach the $4700 threshold for exiting the coverage gap. The co-insurance rate in the gap will be reduced from 100 to 25 percent by 2020 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medicare's catastrophic drug coverage begins after the gap, and recipients pay only a small co-insurance amount or co-payment for covered drugs for the rest of the year. These plans have variable formularies and co-payments as well.",
"   </p>",
"   <p>",
"    People with limited income are eligible for additional assistance from Medicare that may cover 85 to 100 percent of drug costs, depending on the individual's resources.",
"   </p>",
"   <p>",
"    For those currently covered by a supplemental drug plan that meets the government's benchmark, there is no requirement to enroll in Part D. If a decision is subsequently made to enroll in Part D Medicare, no penalty is incurred [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/9\">",
"     9",
"    </a>",
"    ]. However, there is a penalty (at least 1 percent higher monthly premium for every month delayed in enrolling in a plan) for other late-enrollees to discourage eligible participants from delaying selection of a prescription drug plan until they become ill and then start to incur higher drug costs.",
"   </p>",
"   <p>",
"    By 2009, 59 percent of Medicare beneficiaries were enrolled in a Part D plan, 31 percent had other drug coverage, and 10 percent remained without drug benefits, compared to 31 percent who lacked drug benefits in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/10\">",
"     10",
"    </a>",
"    ]. There is evidence that non-drug related costs (mostly related to inpatient and nursing facility care) decreased with implementation of Medicare Part D for those older adults who had previously had limited drug coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/11\">",
"     11",
"    </a>",
"    ]. There is also evidence that appropriate drug utilization does decrease when patients reach the coverage gap (\"doughnut hole&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A systematic review of studies evaluating the impact of Part D coverage found that increasing drug coverage was associated with increased use of both underused essential medications as well increased use of medications that might be overused (such as proton pump inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/14\">",
"     14",
"    </a>",
"    ]. Data are not available regarding the effects of Part D coverage on health outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL COVERAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Medicare Plan (Parts A and B) is a \"fee-for-service\" program. Associated deductibles and co-pays can be expensive, and in the past there was no coverage for pharmaceuticals. Thus, nearly 90 percent of enrollees have purchased some form of supplemental coverage to help reduce out-of-pocket costs. Two programs currently exist to help with such expenses: Medigap and Medicaid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medigap",
"    </span>",
"    &nbsp;&mdash;&nbsp;To help pay for some of the costs in the original Medicare Program and for some care it does not cover, Medicare recipients can purchase private supplemental insurance coverage via a program known as Medigap. Patients must be enrolled in Medicare A and B to purchase this plan; Medigap is not available to those already enrolled in Medicare Advantage. Medigap sets forth standardized plans with several different levels of services provided, known as plans A through N (least to most comprehensive, as defined by standards common to most states). Monthly premiums average between $100 to $200, with higher prices for plans that provide more benefits. All plans cover hospital and outpatient co- payments, and except for the basic \"Plan A,\" they also cover the hospital deductible. A change for 2010 was the coverage for hospice as a core benefit for all plans. Other than plans A and B, the remaining plans cover the co-insurance for the first 100 days of SNF care and help to cover emergency care outside the United States. There are minor differences between the remaining plans, including coverage of the Part B deductible, coverage for home recovery, coverage for preventive services, partial coverage for prescription drug costs, etc. None of the Medigap plans cover long-term care, vision, dental care, hearing aids, private duty nursing, or all of a patient's prescription drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medicaid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicaid is another US state and federally funded health insurance plan for the low income",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disabled recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10484?source=see_link\">",
"     \"Medicaid\"",
"    </a>",
"    .) The qualifying income level and amount of coverage varies from state to state. Those on Medicare with incomes below the poverty level set by their state can receive Medicaid benefits, which usually cover almost all out-of-pocket expenses such as deductibles, co-payments, and Part B premiums for those who qualify.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROVIDER REIMBURSEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Assignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicare sets payment for each service they will cover known as the \"Medicare Approved Amount\" (MAA). Medicare typically pays 80 percent of the approved amount or 80 percent of the actual charges if they are less than this amount. Assignment is an agreement between Medicare and the physician, or other health care provider, that they will accept the MAA as payment in full and will not charge Medicare recipients a higher rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A provider who \"participates\" in Medicare is stating that they will always accept assignments. \"Non-participating\" providers can accept assignment rates on a case-by-case basis, or not at all. When a physician participates in Medicare and accepts assignments, this means that Medicare will pay for 80 percent of the MAA and the patient will pay the remaining 20 percent.",
"   </p>",
"   <p>",
"    Many providers are required by law to participate in Medicare and accept assignment. These include hospitals, rehabilitation and skilled nursing facilities, home health agencies, laboratories, and outpatient physical and occupational therapy providers.",
"   </p>",
"   <p>",
"    However, physicians may opt out of participating. He or she can still bill Medicare for services provided to a Medicare beneficiary, but Medicare will only pay based on a reduced fee scale, ie, 95 percent of the MAA. Furthermore, the physician charge rate is still restricted by Medicare and they can bill no more than 115 percent of the reduced MAA, known as \"the limiting charge.\" Medicare would then pay 80 percent of this reduced amount. Typically, non-participating physicians will bill the patient for the entire amount of the care provided and Medicare reimburses the patient for their 80 percent share [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example may help to clarify this confusing situation. Let's examine the billing for procedure X, for which the physician charges $140. The Medicare Approved Amount (MAA) will likely be set lower &ndash; for this example we'll assume that it is set at $100. For the non-participating physician, Medicare further reduces that rate to $95 (95 percent of the MAA). The physician cannot charge the patient more than $109.25 ($95 X 115 percent). Typically the patient pays the bill, not Medicare. The patient will then submit to Medicare for reimbursement of the claim. In this case Medicare would reimburse the patient $76 ($95 (the MAA) X 80 percent (Medicare share)). The patient would pay the $33.25 difference &ldquo;out-of-pocket.&rdquo;",
"   </p>",
"   <p>",
"    Had the physician been \"participating,\" he could still have charged $140 for procedure X, but the MAA would still have been $100. The difference would be that Medicare would reimburse the physician $80 (80 percent of the MAA) and the patient would have paid the $20 difference \"out-of-pocket.\" Thus, the non-participating physician receives a higher payment amount, but it is at the expense of the patient's higher &ldquo;out-of-pocket&rdquo; amount.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prospective payment system",
"    </span>",
"    &nbsp;&mdash;&nbsp;There was significant resistance from organized medicine when Medicare was initially introduced. In order to overcome this resistance, a fee schedule was developed on a cost-based reimbursement formula for care provided as set out by providers. However, in an attempt to control costs and standardize reimbursements, Medicare implemented a prospective payment system (PPS) in 1983. The foundation of PPS was to combine related medical conditions of hospitalized patients into diagnosis-related groups (DRGs) based on work done by a group of Yale researchers. Once the DRG codes were set, standardized reimbursement was assigned to each code.",
"   </p>",
"   <p>",
"    In essence, a hospital is paid a certain fixed amount based on a patient's diagnosis, regardless of the number of days spent in the hospital or the total costs that the hospital has incurred in caring for the patient. Hospitals that can care for the patient in a short 'length of stay' (LOS) with costs that are less than the fixed DRG payment reap the benefits. However, if the LOS is prolonged and the costs associated with the patient's care are above what the Medicare DRG rate will reimburse, the hospital must absorb those costs and is not permitted to pass them along to Medicare or the patient. Severity of illness and co-morbidity modifiers help to increase the rates, but this system forces hospitals to be as efficient as possible with the services provided.",
"   </p>",
"   <p>",
"    One of the outcomes of this change in reimbursement was to stabilize the Medicare Trust Fund by holding down costs. However, many hospitals, particularly small rural hospitals, have closed because of an inability to survive with the rigorous cuts and reduced payments that they received under PPS. The broader use of capitation payment methods, seen under managed care, in many ways was based on the Medicare DRG payment system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Resource-Based Relative Value Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;While DRGs applied to hospital billing, another method was implemented in 1992 to change physician payment. This is known as the Resource-Based Relative Value Scale (RBRVS). Prior to this time Medicare payments were based on a somewhat arbitrary method of reimbursement for \"customary, prevailing, and reasonable fees.\" The RBRV scale is an attempt to standardize physician payment for services provided, which reflects the relative resources required to provide such services.",
"   </p>",
"   <p>",
"    For non-hospital based ambulatory care there are three recognized relative value units (RVU's):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physician work expenses (time and energy spent)",
"     </li>",
"     <li>",
"      Practice expense (equipment and supplies needed)",
"     </li>",
"     <li>",
"      Malpractice expense",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physician work expense reflects the time and skill required to treat a specific condition. As an example, a physician is paid more for evaluating a new patient than an established patient.",
"   </p>",
"   <p>",
"    These payments are still based on a \"fee-for-service\" mechanism, but require physicians to document more precisely what services are delivered to the patient. Medicare has set forth a template outlining what needs to be documented to support billing at each Evaluation &amp; Management (E&amp;M) level. A physician receives a greater reimbursement for a level 5 E&amp;M encounter than a level 2, but there is considerably more documentation required to support this higher level of billing.",
"   </p>",
"   <p>",
"    The E&amp;M level is based on three components",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The breadth of the history",
"     </li>",
"     <li>",
"      The intricacy of the physical examination",
"     </li>",
"     <li>",
"      The complexity of the medical decision making utilized to treat the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many physicians find such detailed documentation to be an onerous intrusion on their practice, as it takes time away from direct patient care.",
"   </p>",
"   <p>",
"    Each RVU is further adjusted using a broad geographical practice cost index (GPCI). Once a final RVU is assigned, it is converted into a dollar amount by multiplying it by a conversion factor. The conversion factor is influenced by a number of complex variables, including the Medicare Economic Index, new beneficiary enrollment, technology, and volume of services performed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152522\">",
"    <span class=\"h2\">",
"     Sustainable Growth Rate formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sustainable Growth Rate (SGR) formula was introduced in 2002 to hold Medicare costs in check, specifically to control the total Medicare spending on physician services. According to the formula, physician reimbursement rates would be subject to annual cuts, but such cuts have been deferred by Congress, which has either frozen or agreed to slight increases in the rates. Because this &lsquo;deferring&rsquo; action has taken place, the SGR rate reduction for 2011 would have been 24.9 percent. Once again Congress has deferred action on cuts, but the PPACA has reinforced efforts to hold costs under control. Increased emphasis on payment reform mechanisms such as the use of &lsquo;bundled&rsquo; payments and the growth of Accountable Care Organizations (ACOs) is likely [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152571\">",
"    <span class=\"h2\">",
"     Bundling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Medicare Payment Advisory Commission (MedPAC) has recommended a program modification, known as \"bundling.\" The DRG prospective payment mechanism that is currently in place does not include physician and outpatient services; this would change under this revised payment system as Medicare would pay a hospital and its affiliated physicians a fixed amount to cover the costs of providing all services during an episode of care, including inpatient and outpatient services up to 30 days after discharge. It is hoped that this payment mechanism would result in better coordination between inpatient and post-hospital care, and result in higher quality of care when combined with pay-for-performance initiatives [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152578\">",
"    <span class=\"h2\">",
"     Accountable care organizations (ACOs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accountable care organizations (ACOs) represent a further development of the bundling concept. ACOs are hospital-physician organizations that would accept responsibility for the care of a panel of Medicare patients and be paid a flat amount (a global payment) for providing these services. This is an attempt to increase the coordinated organization of care delivered to Medicare beneficiaries to both improve quality and slow spending growth. The ACO concept has been reinforced with the passage of PPACA, which recognizes ACOs as a new Medicare payment model [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Participating ACOs that succeed in offering high-quality care and reducing spending will share in any savings they achieve for the Medicare program according to the Medicare Shared Savings Program described in section 3022 of the Affordable Care Act [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/21\">",
"     21",
"    </a>",
"    ]. While eligible for these incentives, providers can continue to receive traditional Medicare fee-for-service payments under Parts A and B [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns in the medical community about the burden of governance and reporting in the ACO initiative, and the associated costs and financial risk entailed by such a transition, have led CMS to implement additional measures to encourage participation. Among these initiatives are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Advanced Payment Initiative provides up-front capital to qualifying small physician practices and community hospitals that would otherwise be unable to make the ACO transition.",
"     </li>",
"     <li>",
"      A lower-risk pathway allows startup ACOs to choose a &ldquo;savings only&rdquo; track without financial risk during their initial contract period, moving to a performance-based system later (in which there would be higher sharing rates for ACOs willing to risk sharing losses).",
"     </li>",
"     <li>",
"      A streamlined Pioneer ACO Model is offered to facilitate the transition of organizations already experienced with care coordination from a shared-saving payment model to a population-based payment model consistent with the Medicare Shared Savings Program [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MEDICAL STUDENT AND HOUSESTAFF DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicare has issued rules relating to documentation of services provided to Medicare recipients that are performed by medical students and residents. Medicare allows a physician to bill based on a combination of resident and attending documentation for services provided. The teaching attending must clearly document that they were personally involved in the patient&rsquo;s care, which includes either performing the services or directly observing the resident perform the services. Teaching physicians must write a statement indicating their presence and summarize the most important patient-specific elements within each of the required key components. The review of systems (ROS) and the past family and social history (PFSH) do not need to be re-documented if completed by a student or resident. The teaching attending can refer to details of the resident's note for the service provided &ndash; but not for students. While students may document the ROS and the PFSH, all other key elements of the encounter must be documented by the attending physician. The rule requires that the teaching attending perform and write a summary note for all three of the major component activities of a new visit (history, exam, and medical decision making) and for two of the three for an established patient visit.",
"   </p>",
"   <p>",
"    There is an \"exception\" for primary care outpatient services provided by residents. This waiver does not require the attending physician's presence during the provision of \"low-level\" Evaluation and Management (E&amp;M) services (levels 1, 2, and 3). However, for level 4 or 5 services and for any procedures performed the standard rules apply. The attending must still write a note documenting that the case was reviewed with the resident while the patient was in the clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24679/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are related websites and telephone numbers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local resource and patient information",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.medicare.gov/\">",
"     www.medicare.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.eldercare.gov/\">",
"     www.eldercare.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;1-800-MEDICARE",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Office materials",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.medicare.gov/\">",
"     www.medicare.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.aarp.org/\">",
"     www.aarp.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Financial assistance for patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Social Security:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.ssa.gov/prescriptionhelp\">",
"     www.ssa.gov/prescriptionhelp",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1-800-772-1213",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Other financial resource information",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.benefitscheckup.org/\">",
"     www.benefitscheckup.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detailed Medicare information for providers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cms.hhs.gov/home/medicare.asp\">",
"     www.cms.hhs.gov/home/medicare.asp",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    A patient information topic in UpToDate addresses how patients can reduce their medication expenses, which could be of help for patients in the &ldquo;doughnut hole&rdquo; of Part D coverage. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"     \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1678085840\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medicare is a publically-funded health insurance plan in the United States for individuals older than 65 years, those receiving social security disability payments, or those requiring dialysis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basic coverage includes Part A (hospital insurance and some coverage for skilled nursing) and Part B (medical insurance), which is optional, covering some components of outpatient care and physician services. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Basic coverage'",
"      </a>",
"      above.) Part C, or Medicare Advantage, offers coverage through managed care plans (health maintenance organizations or preferred provider organizations). (See",
"      <a class=\"local\" href=\"#H254562329\">",
"       'Part C (Medicare Advantage)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prescription drug coverage, Part D, was implemented in 2004. Coverage for partial drug costs extends to $2780, and catastrophic drug coverage begins after out-of-pocket expenses up to $4700, leaving a &ldquo;doughnut hole&rdquo; where drug coverage is not available. Prescription drug coverage is provided by stand-alone prescription drug plans or as part of a Medicare Advantage plan (Part C). (See",
"      <a class=\"local\" href=\"#H254562397\">",
"       'Part D (Prescription drug coverage)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medigap is private supplemental insurance for individuals enrolled in Medicare A and B and provides different levels of services for additional monthly premiums. Medicaid provides coverage, varying by state, for low-income or disabled recipients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Medigap'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Medicaid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospitals are reimbursed under a prospective payment system, where rates are set by the patient&rsquo;s diagnosis-related group (DRG), rather than by the length of stay, fostering hospital efficiency. Physician reimbursement is based on the resource-based relative value scale (RBRVS), requiring appropriate visit documentation to support billing. Billing requirements for teaching attendants are also specified. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Resource-Based Relative Value Scale'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Medical student and housestaff documentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266986685\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Michael Tutty, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     https://questions.medicare.gov/app/home (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services. file://www.medicare.gov/Publications/Pubs/pdf/10184.pdf (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     Affordable Care Act Medicare Preventive Services Disclaimer. https://www.cms.gov/MLNProducts/downloads/MPS_QuickReferenceChart_1.pdf (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     New Medicare Benefits for 2011. Healthcare.gov  2011. Available at: file://www.healthcare.gov/news/factsheets/2011/01/new-medicare-benefits.html (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/5\">",
"      Card RO. How to conduct a \"welcome to Medicare\" visit. Fam Pract Manag 2005; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/6\">",
"      Hughes C. What you need to know about the Medicare preventive services expansion. Fam Pract Manag 2011; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     www.aarp.org/health/medicare (Accessed on February 02, 2008).",
"    </li>",
"    <li>",
"     Explaining Health Care Reform: Key Changes to the Medicare Part D Drug Benefit Coverage Gap. file://www.kff.org/healthreform/upload/8059.pdf (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     www.aarp.org/health/medicare/drug_coverage (Accessed on January 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/10\">",
"      Neuman P, Cubanski J. Medicare Part D update--lessons learned and unfinished business. N Engl J Med 2009; 361:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/11\">",
"      McWilliams JM, Zaslavsky AM, Huskamp HA. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA 2011; 306:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/12\">",
"      Polinski JM, Kilabuk E, Schneeweiss S, et al. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc 2010; 58:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/13\">",
"      Li P, McElligott S, Bergquist H, et al. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med 2012; 156:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/14\">",
"      Polinski JM, Donohue JM, Kilabuk E, Shrank WH. Medicare Part D's effect on the under- and overuse of medications: a systematic review. J Am Geriatr Soc 2011; 59:1922.",
"     </a>",
"    </li>",
"    <li>",
"     www.aarp.org/health/medicare/supplemental/Articles/a2003-05-02-medicaresupplement.html (Accessed on January 21, 2009).",
"    </li>",
"    <li>",
"     Baldor RA. Managed Care Made Simple, 2nd ed, Blackwell Science, Cambridge, MA 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/17\">",
"      Ginsburg PB. Rapidly evolving physician-payment policy--more than the SGR. N Engl J Med 2011; 364:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/18\">",
"      Hackbarth G, Reischauer R, Mutti A. Collective accountability for medical care--toward bundled Medicare payments. N Engl J Med 2008; 359:3.",
"     </a>",
"    </li>",
"    <li>",
"     Will bundling include doctors? Medicare looking for alternative payment plans. American Medical News. www.ama-assn.org/amednews/2010/01/04/gvsa0104.htm (Accessed on March 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/20\">",
"      Fisher ES, Shortell SM. Accountable care organizations: accountable for what, to whom, and how. JAMA 2010; 304:1715.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid Services. Accountable Care Organizations (ACO). Available at: https://www.cms.gov/ACO/ (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     Medicare Shared Savings Program: Accountable Care Organizations. Centers for Medicare &amp; Medicaid Services. Available at: file://www.cms.gov/sharedsavingsprogram/ (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24679/abstract/23\">",
"      Berwick DM. Making good on ACOs' promise--the final rule for the Medicare shared savings program. N Engl J Med 2011; 365:1753.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services, Centers for Medicare and Medicaid Services. Guidelines for teaching Physicians, Interns, and Residents. https://www.cms.gov/MLNProducts/downloads/gdelinesteachgresfctsht.pdf (Accessed on March 11, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2774 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24679=[""].join("\n");
var outline_f24_6_24679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1678085840\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC COVERAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Part A (the hospital insurance program)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Part B (the medical insurance program)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15408229\">",
"      - Preventive care visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254562329\">",
"      Part C (Medicare Advantage)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H254562397\">",
"      Part D (Prescription drug coverage)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUPPLEMENTAL COVERAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medigap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medicaid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROVIDER REIMBURSEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Assignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prospective payment system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Resource-Based Relative Value Scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2152522\">",
"      Sustainable Growth Rate formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2152571\">",
"      Bundling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2152578\">",
"      Accountable care organizations (ACOs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MEDICAL STUDENT AND HOUSESTAFF DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1678085840\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266986685\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17755\" title=\"table 1\">",
"      Part B premium 2012",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/17/12573\" title=\"table 2\">",
"      Preventive services",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10484?source=related_link\">",
"      Medicaid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24680="Epidemiology and clinical manifestations of chronic lymphocytic leukemia";
var content_f24_6_24680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24680/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/6/24680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B-cell neoplasm small lymphocytic lymphoma (SLL), one of the indolent non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation and laboratory manifestations of CLL will be reviewed here. The diagnosis, differential diagnosis, pathophysiology, molecular biology, and treatment of CLL are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLL is the most common leukemia in Western countries accounting for approximately 30 percent of all leukemias in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/4\">",
"     4",
"    </a>",
"    ]. The disorder is more common in men with a male to female ratio of approximately 1.7:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence rates among men and women in the United States are approximately 6.75 and 3.65 cases per 100,000 population per year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/6\">",
"     6",
"    </a>",
"    ]. In Europe, these incidence rates are 5.87 and 4.01 cases per 100,000 population per year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CLL is considered to be mainly a disease of the elderly, with a median age at diagnosis of 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/8\">",
"     8",
"    </a>",
"    ]; however, it is not unusual to make this diagnosis in younger individuals from 30 to 39 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence increases rapidly with increasing age. It is estimated that 15,680 new cases of CLL will be diagnosed in 2013, 9720 in males, and 5960 in females [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of CLL varies by race and geographic location. In the United States, there is a higher incidence among Caucasians as compared with African Americans or Asian Pacific Islanders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The incidence of CLL is extremely low in Asian countries such as China and Japan, where it is estimated to occur at a frequency that is approximately 10 percent of that seen in countries of the Western world [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The incidence of CLL in Africa is not as low as it is in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic rather than environmental factors are the most likely explanation for these differences. A genetic effect on incidence was initially suggested by observational studies that have shown that Japanese who settled in Hawaii do not have a higher incidence of CLL than native Japanese [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Further support for a genetic effect was provided by a genotyping study in African Americans that demonstrated that this population had a lower frequency of single nucleotide polymorphisms associated with an increased incidence of CLL in other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/17\">",
"     17",
"    </a>",
"    ]. Furthermore, the cytogenetic and molecular genetic characteristics of CLL appear to be similar throughout the world, although one study suggests that the clinical course may be more aggressive in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no clearly discernible occupational or environmental risk factors that predispose to CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Although there has been an increase in all other types of leukemias among atomic bomb survivors, there has been no increase in the incidence of CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In addition, despite a few reports of an excess risk of CLL among farmers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], those with benzene and heavy solvent exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/20,21,24,25\">",
"     20,21,24,25",
"    </a>",
"    ], rubber manufacturing workers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], or those with multiple episodes of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/27\">",
"     27",
"    </a>",
"    ], these associations have not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Family studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLL and other lymphoid, hematologic, and solid tumors occur with higher than expected frequency among first-degree family members of patients with CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. In addition, one study demonstrated that up to 17 percent of first-degree family members of patients with CLL were found by flow cytometry to have monoclonal B-cell lymphocytosis (MBL) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/35\">",
"     35",
"    </a>",
"    ]. Of note, while virtually all cases of CLL are preceded by MBL, only a small percentage of persons with MBL will ultimately develop CLL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Monoclonal B-cell lymphocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of multi-generational familial cases of CLL noted that the median ages at onset in the child (51 years) and parent generations (72 years) were significantly different (ie, genetic anticipation) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/36\">",
"     36",
"    </a>",
"    ]. Although there is no available proof of genetic transmission of this disease, certain genetic polymorphisms may predispose patients to familial cancer, including CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. DNA analysis in a set of monozygotic twins with CLL suggested that the transforming events in CLL occur late in life and result, even in monozygotic twins, in genetically distinct malignant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of candidate chromosomal regions are currently being explored for the presence of susceptibility genes for familial CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/33,42,43\">",
"     33,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL have a wide range of symptoms and physical and laboratory abnormalities at the time of diagnosis. Most patients consult a physician because they have noted painless swelling of lymph nodes, often in the cervical area, which spontaneously wax and wane, but do not altogether disappear.",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients feel entirely well with no symptoms when a routine blood count reveals an absolute lymphocytosis, leading to a diagnosis of CLL. Five to 10 percent of patients present with the typical \"B\" symptoms of lymphoma which include one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unintentional weight loss &ge;10 percent of body weight within the previous six months.",
"     </li>",
"     <li>",
"      Fevers of &gt;100.5&ordm;F (&gt;38&ordm;C) for &ge;2 weeks without evidence of infection.",
"     </li>",
"     <li>",
"      Drenching night sweats without evidence of infection.",
"     </li>",
"     <li>",
"      Extreme fatigue (ie, ECOG Performance status 2 or worse; cannot work or unable to perform usual activities) (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, the presenting features are those of an acquired immunodeficiency disorder, manifested by infections, autoimmune complications such as hemolytic anemia, thrombocytopenia or pure red cell aplasia, or exaggerated reactions to insect stings or bites (especially mosquito). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Laboratory abnormalities'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common abnormal finding on physical examination of the patient with CLL is lymphadenopathy, present in 50 to 90 percent of patients among various series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Lymph node enlargement may be generalized or localized and individual lymph nodes can vary greatly in size. The most commonly affected sites are cervical, supraclavicular, and axillary.",
"   </p>",
"   <p>",
"    Characteristically, enlarged nodes in CLL are firm, rounded, discrete, nontender, and freely mobile upon palpation. Exceptions to these generalizations are encountered, particularly when the nodes have grown rapidly. Occasionally, several enlarged nodes in the same anatomical site (eg, cervical triangle, axilla or femoral-inguinal areas) may become confluent, forming large spherical lymphoid masses. In addition, new lymph nodes may appear in places other than the usual lymph node-bearing sites, such as over the sacrum or the thorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen is the second most frequently enlarged lymphoid organ, being palpably enlarged in 25 to 55 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. As is the case with enlarged lymph nodes, an enlarged spleen in CLL is usually painless, and nontender to palpation, with a sharp edge and a smooth firm surface. Painful and infarcted splenic enlargement is an unusual presenting feature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlargement of the liver may be noted at the time of initial diagnosis in 15 to 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The liver is usually only mildly enlarged, ranging from 2 to 6 cm below the right costal margin, with a span of dullness to percussion of about 10 to 16 cm. Upon palpation, the liver is usually nontender and firm with a smooth surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration with CLL cells may occur in any organ, but, at the time of diagnosis, the skin (leukemia cutis) is the most commonly involved non-lymphoid organ. These lesions most commonly involve the face and can manifest as macules, papules, plaques, nodules, ulcers, or blisters [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/47\">",
"     47",
"    </a>",
"    ]. Diagnosis is made based upon biopsy of the involved skin. Leukemia cutis is seen in fewer than 5 percent of cases and may not significantly affect overall prognosis unless they represent foci of Richter's transformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonspecific secondary cutaneous lesions may be due to infection, bleeding, vasculitis, or paraneoplastic pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/48\">",
"     48",
"    </a>",
"    ]. An exaggerated reaction to insect bites, especially mosquito bites, has been reported, and may alert the clinician to the diagnosis of CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Membranoproliferative glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN) has occasionally been described in CLL, and appears to be a paraneoplastic phenomenon mediated by deposition and possibly processing of cryoprecipitating or noncryoprecipitating M-components [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33064?source=see_link&amp;anchor=H5#H5\">",
"     \"Glomerular diseases due to nonamyloid fibrillar deposits\", section on 'Immunotactoid glomerulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually any lymphoid tissue may be enlarged at diagnosis, including Waldeyer's ring in the pharynx. In contrast to other lymphomas, gastrointestinal mucosal involvement is rarely seen in CLL. Similarly, meningeal leukemia is unusual at the time of initial presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lymphocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most noteworthy laboratory abnormality found in CLL is lymphocytosis in the peripheral blood and bone marrow. Although the absolute blood lymphocyte threshold for diagnosing CLL has been placed at",
"    <span class=\"nowrap\">",
"     &gt;5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    B lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/44\">",
"     44",
"    </a>",
"    ], a significant proportion of patients present with counts as high as",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    [100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L].",
"    </span>",
"    As an example, in one study, 30 percent of patients entering a therapeutic trial had a total white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL",
"    </span>",
"    [100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although very unusual, it should be noted that when blood leukocyte counts are greatly in excess of",
"    <span class=\"nowrap\">",
"     200,000/microL,",
"    </span>",
"    the increased number of cellular elements may result in abnormally high whole blood viscosity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia, anemia and thrombocytopenia may be observed at the time of initial diagnosis, and are usually not severe. These can be related to autoimmune hemolytic anemia, pure red cell aplasia, autoimmune thrombocytopenia, or agranulocytosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CLL have an increased incidence of autoimmune hemolytic anemia (AIHA). The direct antiglobulin (Coombs') test (DAT) may be positive at some time during the course of the disease in up to 35 percent of cases; overt AIHA occurs in 11 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/54\">",
"       54",
"      </a>",
"      ]. The positive and negative predictive value of the DAT was reported as part of a prospective clinical trial in patients with CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/55\">",
"       55",
"      </a>",
"      ]. The DAT status was able to correctly predict the development of AIHA in 83 percent of cases with a positive predictive value (chance that a DAT-positive patient will develop AIHA) of 28 percent and a negative predictive value (chance that a DAT-negative patient will remain free of AIHA) of 93 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Genesis of antibody production'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link\">",
"       \"Autoimmune complications following purine analog therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pure red cell aplasia (PRCA) is rare, occurring in approximately 0.5 percent of patients. However, if this disorder is specifically sought for via bone marrow aspiration and absolute reticulocyte count, PRCA may be found in up to 6 percent of patients with CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/54\">",
"       54",
"      </a>",
"      ]. Unlike AIHA, PRCA may occur early in the course of CLL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link&amp;anchor=H2#H2\">",
"       \"Acquired pure red cell aplasia\", section on 'Etiology and pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune thrombocytopenia is diagnosed when a bone marrow biopsy shows adequate numbers of megakaryocytes but the peripheral blood has an abnormally low platelet count. This complication occurs in 2 to 3 percent of patients with CLL, and may be the event that initially brings the patient to medical attention [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/54\">",
"       54",
"      </a>",
"      ]. Retrospective studies have reported varying impacts of immune thrombocytopenia on the clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, agranulocytosis may be encountered in CLL (approximately 0.5 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"       \"Overview of neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia has prognostic implications that are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immunoglobulin abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogammaglobulinemia is present in approximately 8 percent of patients at the time of initial diagnosis and may develop in up to two-thirds of patients later in the course of the disease. Usually all three immunoglobulin classes (IgG, IgA, and IgM) are decreased, but in some patients only one or two may be low. Significant degrees of hypogammaglobulinemia and neutropenia, when present, result in increased vulnerability of CLL patients to major bacterial infections.",
"   </p>",
"   <p>",
"    Polyclonal increases in gamma globulins can be seen in up to 15 percent of patients, while a monoclonal protein, usually of the same class as the surface membrane immunoglobulin, is present in up to 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 109 persons who had developed CLL and had serially collected prediagnostic serum samples, the prevalences of an abnormal free light chain ratio, monoclonal protein (M-protein), and hypogammaglobulinemia before CLL diagnosis were 38, 13, and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/58\">",
"     58",
"    </a>",
"    ]. M-proteins and an abnormal free light chain ratio were detected up to 9.8 years before CLL diagnosis in 48 of the 109 subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22390998#H22390998\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other abnormal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no characteristic abnormalities in blood chemistry, but elevated levels of serum lactate dehydrogenase (LDH) and beta-2 microglobulin were found in approximately 60 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24680/abstract/53\">",
"     53",
"    </a>",
"    ]. Elevations of uric acid, hepatic enzymes (ALT or AST) and, rarely, calcium may also be observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm) characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. The disorder is considered to be identical (ie, one disease at different stages) to the mature B-cell neoplasm small lymphocytic lymphoma (SLL). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CLL is the most common leukemia in Western countries, accounting for approximately 30 percent of all leukemias in the United States. It has a male predominance and is more common in Caucasians. The median age at diagnosis is 70 years. There are no clearly discernible occupational or environmental risk factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients present with painless swelling of lymph nodes, often in the cervical area, which spontaneously wax and wane, but do not altogether disappear. Approximately 25 percent of patients are asymptomatic at diagnosis and only come to the physician's attention based upon abnormalities found on routine blood counts. Less common presentations include constitutional \"B\" symptoms of lymphoma, symptoms related to an acquired immunodeficiency, or autoimmune complications. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphadenopathy, splenomegaly, and hepatomegaly are the most common findings on physical examination at the time of diagnosis. CLL cells may infiltrate and disrupt the function of any organ. At the time of diagnosis, the skin (leukemia cutis) is the most commonly involved non-lymphoid organ. Gastrointestinal mucosal involvement and meningeal leukemia are rare. Membranoproliferative glomerulonephritis (MPGN) is seen on occasion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with CLL have a prominent lymphocytosis in the peripheral blood and bone marrow at diagnosis. Neutropenia, anemia and thrombocytopenia may also be observed at the time of initial diagnosis, and are usually of relatively mild degree. These can be related to autoimmune hemolytic anemia, pure red cell aplasia, autoimmune thrombocytopenia, or agranulocytosis. Other laboratory abnormalities at presentation may include hypo- and hypergammaglobulinemia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/1\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/3\">",
"      Tsimberidou AM, Wen S, O'Brien S, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007; 25:4648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/4\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/5\">",
"      Hern&aacute;ndez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995; 75:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/6\">",
"      Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/7\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/8\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/9\">",
"      Kobayashi T, Kita K, Ohno T, Shirakawa S. [Chronic lymphocytic leukemia in Japan]. Rinsho Ketsueki 1990; 31:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/10\">",
"      Yang C, Zhang X. Incidence survey of leukemia in China. Chin Med Sci J 1991; 6:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/11\">",
"      Zheng W, Linet MS, Shu XO, et al. Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China. Cancer Causes Control 1993; 4:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/12\">",
"      Wu SJ, Huang SY, Lin CT, et al. The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood 2010; 116:4430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/13\">",
"      Fleming AF. The epidemiology of lymphomas and leukaemias in Africa--an overview. Leuk Res 1985; 9:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/14\">",
"      Oloo AJ, Ogada TA. Chronic lymphocytic leukaemia (CLL): clinical study at Kenyatta National Hospital (KNH). East Afr Med J 1984; 61:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/15\">",
"      Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/16\">",
"      Yanagihara ET, Blaisdell RK, Hayashi T, Lukes RJ. Malignant lymphoma in Hawaii-Japanese: a retrospective morphologic survey. Hematol Oncol 1989; 7:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/17\">",
"      Coombs CC, Rassenti LZ, Falchi L, et al. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood 2012; 120:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/18\">",
"      Asou H, Takechi M, Tanaka K, et al. Japanese B cell chronic lymphocytic leukaemia: a cytogenetic and molecular biological study. Br J Haematol 1993; 85:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/19\">",
"      Gunawardana C, Austen B, Powell JE, et al. South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients. Br J Haematol 2008; 142:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/20\">",
"      Blair A, White DW. Leukemia cell types and agricultural practices in Nebraska. Arch Environ Health 1985; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/21\">",
"      Burmeister LF, Van Lier SF, Isacson P. Leukemia and farm practices in Iowa. Am J Epidemiol 1982; 115:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/22\">",
"      Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994; 137:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/23\">",
"      Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Chronic lymphocytic leukaemia and radiation: findings among workers at five US nuclear facilities and a review of the recent literature. Br J Haematol 2007; 139:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/24\">",
"      Arp EW Jr, Wolf PH, Checkoway H. Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry. J Occup Med 1983; 25:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/25\">",
"      Monson RR, Fine LJ. Cancer mortality and morbidity among rubber workers. J Natl Cancer Inst 1978; 61:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/26\">",
"      McMichael AJ, Andjelkovic DA, Tyroler HA. Cancer mortality among rubber workers: an epidemiologic study. Ann N Y Acad Sci 1976; 271:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/27\">",
"      Landgren O, Rapkin JS, Caporaso NE, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007; 109:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/28\">",
"      Brandt L. Environmental factors and leukaemia. Med Oncol Tumor Pharmacother 1985; 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/29\">",
"      Cuttner J. Increased incidence of hematologic malignancies in first-degree relatives of patients with chronic lymphocytic leukemia. Cancer Invest 1992; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/30\">",
"      Yuille MR, Matutes E, Marossy A, et al. Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br J Haematol 2000; 109:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/31\">",
"      Goldin LR, Ishibe N, Sgambati M, et al. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol 2003; 121:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/32\">",
"      Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004; 104:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/33\">",
"      Fuller SJ, Papaemmanuil E, McKinnon L, et al. Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. Br J Haematol 2008; 142:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/34\">",
"      Brown JR, Neuberg D, Phillips K, et al. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol 2008; 143:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/35\">",
"      Goldin LR, Lanasa MC, Slager SL, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol 2010; 151:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/36\">",
"      Wiernik PH, Ashwin M, Hu XP, et al. Anticipation in familial chronic lymphocytic leukaemia. Br J Haematol 2001; 113:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/37\">",
"      Calin GA, Trapasso F, Shimizu M, et al. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 2005; 352:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/38\">",
"      Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 24:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/39\">",
"      Crowther-Swanepoel D, Wild R, Sellick G, et al. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood 2008; 111:5691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/40\">",
"      Campa D, Butterbach K, Slager SL, et al. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer 2012; 131:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/41\">",
"      Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100:4609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/42\">",
"      Sellick GS, Webb EL, Allinson R, et al. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet 2005; 77:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/43\">",
"      Ng D, Toure O, Wei MH, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood 2007; 109:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/44\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/45\">",
"      Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/46\">",
"      Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/47\">",
"      Agnew KL, Ruchlemer R, Catovsky D, et al. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/48\">",
"      Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 2007; 48:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/49\">",
"      WEED RI. EXAGGERATED DELAYED HYPERSENSITIVITY TO MOSQUITO BITES IN CHRONIC LYMPHOCYTIC LEUKEMIA. Blood 1965; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/50\">",
"      Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/51\">",
"      Favre G, Courtellemont C, Callard P, et al. Membranoproliferative glomerulonephritis, chronic lymphocytic leukemia, and cryoglobulinemia. Am J Kidney Dis 2010; 55:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/52\">",
"      Da'as N, Polliack A, Cohen Y, et al. Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 2001; 67:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/53\">",
"      Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/54\">",
"      Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/55\">",
"      Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008; 111:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/56\">",
"      Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/57\">",
"      Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/58\">",
"      Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009; 114:4928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24680/abstract/59\">",
"      Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011; 118:2821.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4488 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24680=[""].join("\n");
var outline_f24_6_24680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Family studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lymphocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cytopenias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immunoglobulin abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other abnormal findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33064?source=related_link\">",
"      Glomerular diseases due to nonamyloid fibrillar deposits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=related_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24681="Approach to the patient with thrombocytosis";
var content_f24_6_24681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with thrombocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24681/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24681/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/6/24681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/6/24681/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/6/24681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal platelet count in adults (mean &plusmn; 2 standard deviations) ranges from 150,000 to",
"    <span class=\"nowrap\">",
"     450,000/microL.",
"    </span>",
"    In this review, thrombocytosis will be arbitrarily defined as a platelet count",
"    <span class=\"nowrap\">",
"     &gt;500,000/microL,",
"    </span>",
"    since the above definition means that 2.5 percent of the normal population will have a platelet count",
"    <span class=\"nowrap\">",
"     &gt;450,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    any patient with newly recognized thrombocytosis, two questions should be addressed in a timely fashion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the thrombocytosis a reactive phenomenon or a marker for the presence of a clonal (neoplastic, autonomous) hematologic disorder?",
"     </li>",
"     <li>",
"      What is the immediate risk to the patient from the increased platelet count and how should it be managed?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the approach to the patient with thrombocytosis, with a view to answering these two clinically important questions. The diagnosis, clinical manifestations, treatment, and prognosis of essential thrombocythemia (essential thrombocytosis) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link\">",
"     \"Prognosis and treatment of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated platelet count may be caused by either a cytokine-driven (reactive) mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], or may be the result of growth factor-independent (autonomous) overproduction of platelets by",
"    <span class=\"nowrap\">",
"     clonal/neoplastic",
"    </span>",
"    megakaryocytes, as in one of the myeloproliferative or myelodysplastic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. For the purposes of this discussion, the following definitions (and their abbreviations) will apply:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reactive thrombocytosis (RT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive thrombocytosis (RT) refers to thrombocytosis in the absence of a chronic myeloproliferative or myelodysplastic disorder, in patients who have a medical or surgical condition likely to be associated with an increased platelet count, and in whom the platelet count normalizes, or is expected to normalize, after resolution of this condition. Examples are recent surgery, bacterial infection, and trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autonomous thrombocytosis (AT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomous thrombocytosis (AT) refers to thrombocytosis in the presence of an established diagnosis of a chronic myeloproliferative or myelodysplastic disorder. Examples of chronic myeloproliferative neoplasms associated with thrombocytosis are essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), and chronic myeloid leukemia (CML). The most common of the myelodysplastic disorders associated with thrombocytosis are the 5q- syndrome and RARS with thrombocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4008100#H4008100\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Complete blood count'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Essential thrombocythemia (ET)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential thrombocythemia (essential thrombocytosis, ET) is one of the myeloproliferative neoplasms, as noted above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the diagnosis of three of the myeloproliferative neoplasms (PV, PMF, and CML) can be made by demonstrating clonal (eg, chromosomal)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autonomous (growth-factor independent) characteristics, essential thrombocythemia (ET) is generally diagnosed by excluding the other myeloproliferative neoplasms as well as all causes for reactive thrombocytosis. As a result, use of the terms \"clonal\" and \"autonomous\" in this review, although not rigorously correct for all patients with ET, will be meant to include all of the recognized chronic myeloproliferative and myelodysplastic disorders.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REACTIVE THROMBOCYTOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A listing of the causes of reactive thrombocytosis (RT) in adults and children is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"     table 1",
"    </a>",
"    ). RT is much more frequent than autonomous thrombocytosis in both children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/4,7\">",
"     4,7",
"    </a>",
"    ] and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In our own series of 91 consecutive patients with a platelet count",
"    <span class=\"nowrap\">",
"     &gt;600,000/microL,",
"    </span>",
"    RT was diagnosed in 70 percent, autonomous thrombocytosis in 22 percent, and a combination of the two in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/11\">",
"     11",
"    </a>",
"    ]. The causes of RT in this group included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection &mdash; 31 percent",
"     </li>",
"     <li>",
"      Infection plus postsurgical status &mdash; 27 percent",
"     </li>",
"     <li>",
"      Postsurgical status &mdash; 16 percent",
"     </li>",
"     <li>",
"      Malignancy &mdash; 9 percent",
"     </li>",
"     <li>",
"      Postsplenectomy state &mdash; 9 percent",
"     </li>",
"     <li>",
"      Acute blood loss or iron deficiency &mdash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Extreme thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is a much more frequent cause of thrombocytosis than autonomous thrombocytosis even when cases with extreme thrombocytosis (platelet count",
"    <span class=\"nowrap\">",
"     &gt;1,000,000/microL)",
"    </span>",
"    are considered. As an example, in a study of 280 consecutive patients with a platelet count",
"    <span class=\"nowrap\">",
"     &gt;1,000,000/microL,",
"    </span>",
"    RT was diagnosed in 82 percent and a myeloproliferative disorder (ie, autonomous thrombocytosis) in 14 percent; the etiology was uncertain in 4 percent. The causes for extreme RT were [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection &mdash; 31 percent",
"     </li>",
"     <li>",
"      Postsplenectomy or hyposplenism &mdash; 19 percent",
"     </li>",
"     <li>",
"      Malignancy &mdash; 14 percent",
"     </li>",
"     <li>",
"      Trauma &mdash; 14 percent",
"     </li>",
"     <li>",
"      Inflammation (noninfectious) &mdash; 9 percent",
"     </li>",
"     <li>",
"      Blood loss &mdash; 6 percent",
"     </li>",
"     <li>",
"      Rebound thrombocytosis &mdash; 3 percent",
"     </li>",
"     <li>",
"      Uncertain cause &mdash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thrombopoietic growth factors (eg, thrombopoietin, IL-6) have been implicated as the cause of RT in various infectious, inflammatory, malignant, necrotic, and traumatic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A similar cytokine-driven process may be responsible for postsplenectomy RT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/15\">",
"     15",
"    </a>",
"    ]; the functional asplenia associated with celiac sprue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/16\">",
"     16",
"    </a>",
"    ] and systemic amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/17\">",
"     17",
"    </a>",
"    ]; iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/18\">",
"     18",
"    </a>",
"    ]; rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/19\">",
"     19",
"    </a>",
"    ]; or as a rebound effect following drug- or alcohol-associated thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=see_link&amp;anchor=H11#H11\">",
"     \"Alcohol abuse and hematologic disorders\", section on 'Rebound thrombocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of cause, a high platelet count has the potential to be associated with vasomotor (headache, visual symptoms, lightheadedness, atypical chest pain, acral dysesthesia, erythromelalgia), thrombotic, or bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. However, these events are much less likely to occur in association with reactive thrombocytosis than autonomous thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of autonomous thrombocytosis with vasomotor symptoms, thrombosis, and bleeding is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. As an example, in a study of 280 consecutive patients with a platelet count",
"    <span class=\"nowrap\">",
"     &gt;1,000,000/microL,",
"    </span>",
"    the rates of significant thrombosis and hemorrhage for patients with autonomous thrombocytosis were both 24 percent, while they were 1 and 3 percent, respectively, for patients with reactive thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the degree of thrombocytosis cannot be used to predict the likelihood of autonomous thrombocytosis (AT) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/12\">",
"     12",
"    </a>",
"    ]. Although a clinical presentation that includes thrombo-hemorrhagic manifestations suggests the diagnosis of AT, most patients with the myeloproliferative disorder essential thrombocythemia (ET) are initially asymptomatic. Furthermore, only one-third of patients with ET display associated vasomotor symptoms, leukocytosis, or palpable splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/30\">",
"     30",
"    </a>",
"    ]. Similarly, bleeding (5 percent) and thrombotic (15 percent) complications during the course of ET are relatively infrequent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPURIOUS THROMBOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions can cause the platelet count to be spuriously elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mixed cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mixed cryoglobulinemia may have a temperature-dependent increase in leukocyte and platelet counts when blood samples are tested at temperatures of 30&ordm;C or less. This can result in WBC counts as high as",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and a doubling of the platelet count, both of which are attributed to various sizes of precipitated cryoglobulin particles, which may be counted as white blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    platelets in automated cell counters [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This effect is increased if the sample is allowed to cool to lower temperatures and disappears if the sample is kept at body temperature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cytoplasmic fragments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare causes of spurious thrombocytosis include the presence of circulating cytoplasmic fragments in patients with leukemia or lymphoma, or when red blood cell fragmentation occurs in severe hemolysis or burns [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In such cases, small cytoplasmic fragments and even extremely microcytic red blood cells may be counted as platelets by automated cell counters which measure platelets by size criteria alone; examination of the peripheral smear will confirm the spurious nature of the \"thrombocytosis.\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H7#H7\">",
"     \"Automated hematology instrumentation\", section on 'Platelet counting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H23#H23\">",
"     \"Automated hematology instrumentation\", section on 'Platelet error flags'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PSEUDOHYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium is released from platelets that have aggregated. As a result, the measured",
"    <strong>",
"     serum",
"    </strong>",
"    potassium concentration may be as high as 9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in patients with marked thrombocytosis. Pseudohyperkalemia may on occasion be a clue to the presence of thrombocytosis, but it causes no symptoms, as",
"    <strong>",
"     plasma",
"    </strong>",
"    levels of potassium are not altered in the presence of thrombocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Pseudohyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once thrombocytosis has been reported, it should be confirmed by repeat testing and examination of the peripheral blood smear, in order to exclude cases of spurious thrombocytosis (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Spurious thrombocytosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The importance of repeat testing was shown in a study of 10,000 residents of Vicenza, Italy, in whom 99 (1 percent) had an initial platelet count",
"    <span class=\"nowrap\">",
"     &gt;400,000/microL,",
"    </span>",
"    a cutoff value approximately equal to the 99th percentile for the platelet count for men and women in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/37\">",
"     37",
"    </a>",
"    ]. The platelet count was",
"    <span class=\"nowrap\">",
"     &gt;400,000/microL",
"    </span>",
"    in only 8 of the 99 patients (8 percent) on repeat testing at a median interval of eight months (range: 6 to 14 months).",
"   </p>",
"   <p>",
"    If thrombocytosis is confirmed by repeat testing and evaluation of the peripheral smear, the initial step is to perform a comprehensive history and physical examination, and to determine, using available records when possible, the duration of the patient's thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/31\">",
"     31",
"    </a>",
"    ]. Special attention should be paid to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent trauma or surgery",
"     </li>",
"     <li>",
"      Prior surgical removal of the spleen",
"     </li>",
"     <li>",
"      Local or systemic complaints suggesting infection or inflammation",
"     </li>",
"     <li>",
"      Present and past history of bleeding, thrombosis, or iron deficiency",
"     </li>",
"     <li>",
"      Prior diagnosis of a chronic hematologic disorder",
"     </li>",
"     <li>",
"      Weight loss, fatigue, and other systemic complaints suggesting the presence of a malignancy",
"     </li>",
"     <li>",
"      Medication use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This initial evaluation alone should be sufficient to exclude many of the common causes of reactive thrombocytosis (",
"    <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of thrombocytosis should begin with a complete blood count with examination of the peripheral blood smear, and a serum ferritin concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reactive thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations suggest the presence of reactive thrombocytosis at this point in the workup:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low serum ferritin level is diagnostic of iron deficiency, with a specificity approaching 100 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\"",
"      </a>",
"      .) Patients with iron deficiency and anemia will also have hypochromic (reduced mean corpuscular hemoglobin, MCH) and microcytic (reduced mean corpuscular volume, MCV) red blood cells (RBCs) on the peripheral blood smear (",
"      <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"       picture 1",
"      </a>",
"      ) and on RBC indices obtained as a part of the complete blood count.",
"     </li>",
"     <li>",
"      Patients who have been splenectomized or have reduced splenic function (hyposplenism) or a congenitally absent spleen (asplenia) will have nuclear fragments (Howell-Jolly bodies) in their red blood cells (",
"      <a class=\"graphic graphic_picture graphicRef60588 \" href=\"UTD.htm?38/45/39638\">",
"       picture 2",
"      </a>",
"      ), along with a variable number of target cells (",
"      <a class=\"graphic graphic_picture graphicRef80318 \" href=\"UTD.htm?4/3/4151\">",
"       picture 3",
"      </a>",
"      ) and misshapen RBCs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H5#H5\">",
"       \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Hyposplenism and asplenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with inflammatory or infectious conditions are likely to have neutrophilic leukocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link\">",
"       \"Causes of neutrophilia\"",
"      </a>",
"      .) The presence of increased numbers of neutrophilic band forms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metamyelocytes (ie, a \"left shift\"), along with neutrophilic vacuolization, toxic granulation, and D&ouml;hle bodies, is suggestive of infection (",
"      <a class=\"graphic graphic_picture graphicRef70248 \" href=\"UTD.htm?7/17/7449\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29511?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to the patient with neutrophilia\", section on 'Detection of infection or inflammation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If these initial tests and observations are unrevealing, measurement of nonspecific markers of infection or inflammation may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/38\">",
"     38",
"    </a>",
"    ]; these include serum C-reactive protein (CRP) concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], erythrocyte sedimentation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/38,40\">",
"     38,40",
"    </a>",
"    ], plasma fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/41\">",
"     41",
"    </a>",
"    ], and ferritin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/38\">",
"     38",
"    </a>",
"    ]. All would be expected to be increased in patients with reactive thrombocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of the serum concentration of CRP, which serves as a surrogate marker for interleukin (IL)-6, should be normal in uncomplicated autonomous thrombocytosis (AT) and increased in most cases of reactive thrombocytosis (RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/1,11,38,39,42,43\">",
"     1,11,38,39,42,43",
"    </a>",
"    ]. In one study of 91 patients with thrombocytosis, levels of CRP (normal: &lt;1.0",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    were &gt;1.0 and &gt;4.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in 10 and zero percent, respectively, of 20 patients with AT, whereas they were above these cutoff values in 76 and 52 percent, respectively, in the patients with RT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a normal level of CRP or IL-6 is not specific for AT.",
"   </p>",
"   <p>",
"    Although discernible differences may exist, plasma thrombopoietin concentrations are in general not helpful in distinguishing AT from RT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/42,44-46\">",
"     42,44-46",
"    </a>",
"    ]. Some investigators have suggested that the utilization of platelet indices (count, volume, and distribution width) may be of benefit in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, a substantial degree of overlap lessens the value of these measurements. Similarly, platelet function tests are neither sufficiently sensitive nor reliable in distinguishing AT from RT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/28,49\">",
"     28,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene expression (platelet RNA) profiling has been employed to make distinctions among the various causes of clonal and nonclonal thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Autonomous thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a reactive process has been ruled out, the next step is to accurately classify the thrombocytosis as being due to one of the defined myeloproliferative or myelodysplastic disorders. In general, autonomous thrombocytosis (AT) is a reasonable diagnostic possibility in a patient with chronic thrombocytosis, normal iron stores, and an intact spleen.",
"   </p>",
"   <p>",
"    Patients with chronic myeloid leukemia (CML), primary myelofibrosis (PMF), polycythemia vera (PV), a number of myelodysplastic syndrome variants (MDS), atypical CML, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) can sometimes present with thrombocytosis as a prominent feature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, all patients in whom a reactive process cannot be identified require a bone marrow examination with reticulin staining and cytogenetic studies. The following findings are helpful in making these diagnoses:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chronic myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with chronic myeloid leukemia (CML) present with splenomegaly, leukocytosis with circulating early granulocyte forms, thrombocytosis, and low levels of leukocyte alkaline phosphatase activity. The diagnosis of CML is established via the presence of the Philadelphia chromosome, the",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    fusion product, or peripheral blood fluorescence in situ hybridization to demonstrate the chromosomal translocation characteristic of CML [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Polycythemia vera",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with polycythemia vera (PV) have an increased red blood cell mass, splenomegaly, a normal arterial oxygen saturation, a low serum concentration of erythropoietin, and positivity for the JAK2 mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Primary myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients with primary myelofibrosis (PMF) have splenomegaly and the presence of nucleated RBCs, teardrop RBC forms, and early white blood cell precursors on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef68110 graphicRef55274 \" href=\"UTD.htm?18/50/19242\">",
"     picture 5A-B",
"    </a>",
"    ). The presence of substantial bone marrow fibrosis also favors this diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef69139 \" href=\"UTD.htm?24/19/24886\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Myelodysplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes may occasionally be associated with thrombocytosis, variable degrees of anemia, leukocytosis or leukopenia, ringed sideroblasts, disordered cellular maturation (dysplasia) (",
"    <a class=\"graphic graphic_picture graphicRef71990 \" href=\"UTD.htm?4/45/4816\">",
"     picture 7",
"    </a>",
"    ), and characteristic clonal chromosomal abnormalities that occur in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=see_link&amp;anchor=H256821606#H256821606\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on '5q- syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4008100#H4008100\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Complete blood count'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Acute myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare patients with acute myeloid leukemia may have thrombocytosis, in association with chromosome abnormalities and the presence of abnormal megakaryocytes on bone marrow examination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H11#H11\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 't(3;3) and inv(3) in AML with thrombocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Essential thrombocythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential thrombocythemia (ET) is usually diagnosed by excluding all causes of reactive thrombocytosis as well as all of the other causes of autonomous thrombocytosis. There are no laboratory findings which are pathognomonic for ET. Thus, ET is the working diagnosis when autonomous or clonal thrombocytosis occurs in the absence of the diagnostic features noted above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peripheral blood smear and bone marrow examination in patients with ET may show clusters of giant platelets (",
"    <a class=\"graphic graphic_picture graphicRef61742 \" href=\"UTD.htm?22/0/22536\">",
"     picture 8",
"    </a>",
"    ), megakaryocyte clusters (",
"    <a class=\"graphic graphic_picture graphicRef67362 \" href=\"UTD.htm?24/34/25127\">",
"     picture 9",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild reticulin fibrosis. The rate of cytogenetic abnormalities in ET is less than 5 percent. Current diagnostic criteria for ET require a platelet count of over",
"    <span class=\"nowrap\">",
"     600,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/59\">",
"     59",
"    </a>",
"    ]. However, this criterion was arbitrarily set by the Polycythemia Vera Study Group in order to prepare for therapeutic trials. Thus, the diagnosis of ET is possible in subjects with lower platelet counts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Endogenous colony growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration of endogenous megakaryocyte colony growth (ie, growth in tissue culture without the addition of growth factors) may distinguish essential from reactive thrombocytosis, but not from other chronic myeloid disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/61\">",
"     61",
"    </a>",
"    ]. The same is true with endogenous erythroid colony growth assays [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/62\">",
"     62",
"    </a>",
"    ]. However, such assays are not readily available outside of research laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Expression of the thrombopoietin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preliminary studies, we have demonstrated a significant reduction in megakaryocyte thrombopoietin receptor (c-Mpl) expression pattern by immunohistochemical staining of bone marrow in patients with autonomous thrombocytosis as compared with those with reactive thrombocytosis or normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a histologic study of bone marrow from 164 patients with essential thrombocytosis and 19 with reactive thrombocytosis, the combined presence of the following three criteria was found to be highly sensitive (97 percent) and specific (95 percent) for distinguishing essential thrombocythemia from reactive thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased megakaryocyte c-Mpl expression",
"     </li>",
"     <li>",
"      Marked bone marrow megakaryocyte proliferation",
"     </li>",
"     <li>",
"      Increased bone marrow angiogenesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, validation of this preliminary observation is required before it can be applied for diagnostic use. Expression of c-Mpl in circulating platelets, which would be easier to measure, may be reduced in patients with essential thrombocythemia (ET) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, there may considerable overlap among values in ET, other myeloproliferative disorders, and reactive thrombocytosis, limiting its diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     JAK2 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutation in JAK2 has been noted in almost all patients with PV and RARS-T (refractory anemia with ringed sideroblasts and thrombocytosis), in about 50 percent of patients with ET and PMF, and absent in patients with CML, reactive thrombocytosis, and secondary polycythemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'JAK2 mutations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H1583841#H1583841\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'RARS with thrombocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory clues for these diagnoses are presented above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Autonomous thrombocytosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complications of thrombocytosis are listed below, along with a discussion of their management. As noted above, however, very few patients with reactive thrombocytosis will have symptoms requiring treatment (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Symptoms'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of bleeding, the first step is to discontinue the use of any platelet antiaggregating agent, the most common being",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or one of the nonsteroidal antiinflammatory agents. Initial laboratory evaluation should include a workup for disseminated intravascular coagulation and coagulation factor deficiency. Acquired factor V deficiency is sometimes seen in association with autonomous thrombocytosis and is treated with fresh frozen plasma infusion or platelet concentrates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, extreme thrombocytosis is associated with an acquired type II von Willebrand disease because of abnormal platelet adsorption of circulating von Willebrand factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/68\">",
"     68",
"    </a>",
"    ]. In this instance, immediate platelet apheresis coupled with definitive therapy with a platelet-lowering agent is essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with gastrointestinal (GI) or genitourinary (GU) bleeding, thrombocytosis, and evidence for iron deficiency pose a diagnostic dilemma, as one can never be entirely sure which of the following two scenarios is operative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A primary GI or GU lesion is responsible for the bleeding, leading to iron deficiency and reactive thrombocytosis,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Autonomous thrombocytosis with abnormal platelet function is the primary event, leading to hemorrhagic complications (eg, GI or GU mucosal bleeding), and secondary iron deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three approaches to this problem are possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A course of treatment with iron can be given in order to improve the anemia and thus the platelet count, with the result being a lessened degree of bleeding. This is the least likely scenario, since bleeding is uncommon (3 percent) even in patients with extreme degrees of reactive thrombocytosis (platelet count",
"      <span class=\"nowrap\">",
"       &gt;1,000,000/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Direct endoscopic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiologic evaluation can be undertaken in order to detect the presence of a treatable source of bleeding. This approach is especially relevant if the patient has a prior history of a specific bleeding lesion.",
"     </li>",
"     <li>",
"      A course of treatment with a myelosuppressive agent or a platelet-lowering agent such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"       anagrelide",
"      </a>",
"      can be initiated. This approach is most relevant if the patient has no prior history of iron deficiency, if the spleen is intact, if the C-reactive protein concentration is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/11\">",
"       11",
"      </a>",
"      ], and if there are other signs and symptoms of a chronic hematologic disorder (see above). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link\">",
"       \"Prognosis and treatment of essential thrombocythemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive thrombocytosis (RT) has rarely been associated with thrombosis (see above), and in general does not require specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/69\">",
"     69",
"    </a>",
"    ]. Occlusion of the hepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inferior vena cava (Budd-Chiari syndrome), portal, or splenic vein is suggestive of the presence of autonomous thrombocytosis, especially when this occurs in females under the age of 45 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of the Budd-Chiari syndrome\", section on 'Myeloproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of thrombosis, immediate platelet apheresis is recommended if the platelet count is",
"    <span class=\"nowrap\">",
"     &gt;800,000/microL.",
"    </span>",
"    Concomitantly, therapy with a platelet-lowering agent should be started with the goal of keeping the platelet count below",
"    <span class=\"nowrap\">",
"     400,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/60,71\">",
"     60,71",
"    </a>",
"    ]. Initial laboratory investigation should include a workup for an additional thrombophilic disorder, that includes the determination of proteins C and S, antithrombin, anticardiolipin antibody, plasma homocysteine, and mutations of factors V and II (prothrombin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We usually use anticoagulant therapy for three months in the absence of an additional thrombophilic defect, and six or more months otherwise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Vasomotor symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (eg, 81",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) is effective for controlling vasomotor symptoms in patients with thrombocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Vasomotor symptoms'",
"    </a>",
"    .) Whether aspirin is as effective for the prevention of thrombosis is currently being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?24/6/24681/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H20#H20\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Low-dose aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal platelet count in adults ranges from 150,000 to",
"    <span class=\"nowrap\">",
"     450,000/microL.",
"    </span>",
"    Thrombocytosis here has been arbitrarily defined as a platelet count",
"    <span class=\"nowrap\">",
"     &gt;500,000/microL.",
"    </span>",
"    In such patients the initial diagnostic question is whether thrombocytosis is a reactive phenomenon or a marker for the presence of a hematologic disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once thrombocytosis has been reported, it should be confirmed by repeat testing and examination of the peripheral blood smear, in order to exclude cases of spurious thrombocytosis",
"     </li>",
"     <li>",
"      If thrombocytosis is confirmed by repeat testing, the initial step is to perform a comprehensive history and physical examination. This initial evaluation alone should be sufficient to exclude many of the common causes of reactive thrombocytosis (",
"      <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If a reactive process has been ruled out, the next step is to accurately classify the thrombocytosis as being due to one of the defined myeloproliferative or myelodysplastic disorders. In general, this is a reasonable diagnostic possibility in a patient with chronic thrombocytosis, normal iron stores, and an intact spleen.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/1\">",
"      Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991; 79:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/2\">",
"      Haznedarolu IC, Ertenli I, Ozcebe OI, et al. Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Acta Haematol 1996; 95:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/3\">",
"      Dan K, Gomi S, Inokuchi K, et al. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 1995; 93:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/4\">",
"      Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005; 129:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/5\">",
"      Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/6\">",
"      Schafer AI. Thrombocytosis. N Engl J Med 2004; 350:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/7\">",
"      Yohannan MD, Higgy KE, al-Mashhadani SA, Santhosh-Kumar CR. Thrombocytosis. Etiologic analysis of 663 patients. Clin Pediatr (Phila) 1994; 33:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/8\">",
"      Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J Intern Med 1991; 229:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/9\">",
"      Robbins G, Barnard DL. Thrombocytosis and microthrombocytosis: a clinical evaluation of 372 cases. Acta Haematol 1983; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/10\">",
"      Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 1999; 245:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/11\">",
"      Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994; 97:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/12\">",
"      Buss DH, Cashell AW, O'Connor ML, et al. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/13\">",
"      Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999; 19:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/14\">",
"      Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/15\">",
"      Chuncharunee S, Archararit N, Hathirat P, et al. Levels of serum interleukin-6 and tumor necrosis factor in postsplenectomized thalassemic patients. J Med Assoc Thai 1997; 80 Suppl 1:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/16\">",
"      Croese J, Harris O, Bain B. Coeliac disease. Haematological features, and delay in diagnosis. Med J Aust 1979; 2:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/17\">",
"      Gertz MA, Kyle RA, Greipp PR. Hyposplenism in primary systemic amyloidosis. Ann Intern Med 1983; 98:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/18\">",
"      Deray G, Lejonc JL, Galacteros F. Thrombocytosis as a feature of iron-deficiency therapeutic correction. Arch Intern Med 1984; 144:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/19\">",
"      Ertenli I, Kiraz S, Ozt&uuml;rk MA, et al. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003; 23:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/20\">",
"      Radley JM, Hodgson GS, Thean LE, et al. Increased megakaryocytes in the spleen during rebound thrombocytosis following 5-fluorouracil. Exp Hematol 1980; 8:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/21\">",
"      Haselager EM, Vreeken J. Rebound thrombocytosis after alcohol abuse: a possible factor in the pathogenesis of thromboembolic disease. Lancet 1977; 1:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/22\">",
"      Johnson M, Gernsheimer T, Johansen K. Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg 1995; 22:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/23\">",
"      Kashuk JL, Moore EE, Johnson JL, et al. Progressive postinjury thrombocytosis is associated with thromboembolic complications. Surgery 2010; 148:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/24\">",
"      Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost 2012; 10:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/25\">",
"      Randi ML, Stocco F, Rossi C, et al. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 1991; 22:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/26\">",
"      Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/27\">",
"      van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/28\">",
"      Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/29\">",
"      Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc 1998; 73:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/30\">",
"      Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995; 22:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/31\">",
"      Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/32\">",
"      Zandecki M, Dupriez B, Fenaux P, et al. Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia. Nouv Rev Fr Hematol 1989; 31:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/33\">",
"      Hutchinson CV, Stelfox P, Rees-Unwin KS. Needle-like cryoglobulin crystals presenting as spurious thrombocytosis. Br J Haematol 2006; 135:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/34\">",
"      Ballard HS, Sidhu G. Cytoplasmic fragments causing spurious platelet counts in hairy cell leukemia: ultrastructural characterization. Arch Intern Med 1981; 141:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/35\">",
"      Berkessy S. [Cytoplasm fragmentation of malignant lymphoma cells]. Folia Haematol Int Mag Klin Morphol Blutforsch 1983; 110:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/36\">",
"      Lawrence C, Atac B. Hematologic changes in massive burn injury. Crit Care Med 1992; 20:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/37\">",
"      Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003; 139:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/38\">",
"      Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/39\">",
"      Ishiguro A, Suzuki Y, Mito M, et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol 2002; 116:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/40\">",
"      Espa&ntilde;ol I, Hern&aacute;ndez A, Cort&eacute;s M, et al. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels. Haematologica 1999; 84:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/41\">",
"      Messinezy M, Westwood N, Sawyer B, et al. Primary thrombocythaemia: a composite approach to diagnosis. Clin Lab Haematol 1994; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/42\">",
"      Uppenkamp M, Makarova E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol 1998; 77:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/43\">",
"      Folman CC, Ooms M, Kuenen B B, et al. The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol 2001; 114:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/44\">",
"      Wang JC, Chen C, Novetsky AD, et al. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med 1998; 104:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/45\">",
"      Hou M, Carneskog J, Mellqvist UH, et al. Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis. Eur J Haematol 1998; 61:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/46\">",
"      Cerutti A, Custodi P, Duranti M, et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997; 99:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/47\">",
"      Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem 1997; 43:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/48\">",
"      Sehayek E, Ben-Yosef N, Modan M, et al. Platelet parameters and aggregation in essential and reactive thrombocytosis. Am J Clin Pathol 1988; 90:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/49\">",
"      Okuma M. Thrombocytosis and thrombocythemia: qualitative platelet abnormalities. Nihon Ketsueki Gakkai Zasshi 1989; 52:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/50\">",
"      Gnatenko DV, Zhu W, Xu X, et al. Class prediction models of thrombocytosis using genetic biomarkers. Blood 2010; 115:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/51\">",
"      Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91:3357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/52\">",
"      Patel K, Kelsey P. Primary acquired sideroblastic anemia, thrombocytosis, and trisomy 8. Ann Hematol 1997; 74:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/53\">",
"      Bain BJ. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk Lymphoma 1999; 34:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/54\">",
"      Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/55\">",
"      Vallesp&iacute; T, Imbert M, Mecucci C, et al. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998; 83:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/56\">",
"      Yamamoto K, Nagata K, Tsurukubo Y, et al. A novel translocation t(3;22)(q21;q11) involving 3q21 in myelodysplastic syndrome-derived overt leukemia with thrombocytosis. Leuk Res 2000; 24:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/57\">",
"      Lavabre-Bertrand T, Bourquard P, Chiesa J, et al. Diabetes insipidus revealing acute myelogenous leukaemia with a high platelet count, monosomy 7 and abnormalities of chromosome 3: a new entity? Eur J Haematol 2001; 66:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/58\">",
"      Keung YK, Buss D, Powell BL, Pettenati M. Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemia. Cancer Genet Cytogenet 2002; 136:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/59\">",
"      Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/60\">",
"      Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998; 100:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/61\">",
"      Rolovic Z, Basara N, Gotic M, et al. The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 1995; 90:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/62\">",
"      Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/63\">",
"      Yoon SY, Li CY, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur J Haematol 2000; 65:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/64\">",
"      Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002; 99:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/65\">",
"      Harrison CN, Gale RE, Pezella F, et al. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol 1999; 107:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/66\">",
"      Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2000; 111:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/67\">",
"      Hasegawa DK, Bennett AJ, Coccia PF, et al. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood 1980; 56:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/68\">",
"      Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997; 23:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/69\">",
"      Coon WW, Penner J, Clagett P, Eos N. Deep venous thrombosis and postsplenectomy thrombocytosis. Arch Surg 1978; 113:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/70\">",
"      De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/71\">",
"      Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/6/24681/abstract/72\">",
"      Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol 1997; 97:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6682 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24681=[""].join("\n");
var outline_f24_6_24681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reactive thrombocytosis (RT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autonomous thrombocytosis (AT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Essential thrombocythemia (ET)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REACTIVE THROMBOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Extreme thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPURIOUS THROMBOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mixed cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cytoplasmic fragments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PSEUDOHYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reactive thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Autonomous thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Endogenous colony growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Expression of the thrombopoietin receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      JAK2 mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Vasomotor symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6682|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22232\" title=\"picture 1\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39638\" title=\"picture 2\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4151\" title=\"picture 3\">",
"      Target cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/17/7449\" title=\"picture 4\">",
"      Toxic granulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 5A\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43606\" title=\"picture 5B\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/19/24886\" title=\"picture 6\">",
"      Myelofibrosis marrow collagen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/45/4816\" title=\"picture 7\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/0/22536\" title=\"picture 8\">",
"      Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/34/25127\" title=\"picture 9\">",
"      Ess thrombocythemia marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6682|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/7/32892\" title=\"table 1\">",
"      Causes reactive thrombocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29511?source=related_link\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_6_24682="Endoscopy snare billie club";
var content_f24_6_24682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61271%7EGAST%2F76634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61271%7EGAST%2F76634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Endoscopic view and snare of the Billie club",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A polypectomy snare is deployed around the Billie club and gentle traction under direct visualization is used to guide the foreign body toward the rectum for transanal extraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Justin A Maykel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Snare extraction of the Billie club",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture demonstrating the Billie club following successful transanal extraction. The colonoscope is also visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Justin A Maykel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24682=[""].join("\n");
var outline_f24_6_24682=null;
var title_f24_6_24683="Ann Arbor modification ENSAT staging ACC";
var content_f24_6_24683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F86178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F86178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ann Arbor modification of the ENSAT (European Network for the Study of Adrenal Tumors) staging system for adrenocortical cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        ENSAT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ann Arbor modification of ENSAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 1",
"        </strong>",
"       </td>",
"       <td>",
"        T1, N0, M0",
"       </td>",
"       <td>",
"        Stage 1+ low-grade stage 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 2",
"        </strong>",
"       </td>",
"       <td>",
"        T2, N0, M0",
"       </td>",
"       <td>",
"        High-grade stage 2+ low-grade stage 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 3",
"        </strong>",
"       </td>",
"       <td>",
"        T3-4, N0, M0 T1-4, N1, M0",
"       </td>",
"       <td>",
"        High-grade stage 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stage 4",
"        </strong>",
"       </td>",
"       <td>",
"        Any M1",
"       </td>",
"       <td>",
"        Stage 4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 2010; 395:955. Copyright &copy; 2010; with kind permission from Springer Science + Business Media B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24683=[""].join("\n");
var outline_f24_6_24683=null;
var title_f24_6_24684="Major causes of hyponatremia";
var content_f24_6_24684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hyponatremia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders in which ADH levels are elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Effective circulating volume depletion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        True volume depletion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thiazide diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syndrome of inappropriate ADH secretion, including reset osmostat pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hormonal changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders in which ADH levels may be appropriately suppressed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary polydipsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beer drinker's potomania",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hyponatremia with normal or elevated plasma osmolality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        High plasma osmolality (effective osmols)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mannitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        High plasma osmolality (ineffective osmols)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol intoxication with an elevated serum alcohol concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Normal plasma osmolality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudohyponatremia (laboratory artifact)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        High triglycerides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cholestatic and obstructive jaundice (lipoprotein X)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Absorption of irrigant solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Glycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sorbitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mannitol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24684=[""].join("\n");
var outline_f24_6_24684=null;
var title_f24_6_24685="Genetic terms";
var content_f24_6_24685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic terms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Term",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genotype",
"      </td>",
"      <td>",
"       The genetic blueprint",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenotype",
"      </td>",
"      <td>",
"       The translation of the genotype into the physical or biochemical manifestation in an individual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Penetrance",
"      </td>",
"      <td>",
"       The frequency with which the genotype results in any phenotypic changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Variable expressivity",
"      </td>",
"      <td>",
"       The range of phenotypic changes (age of onset, severity of disease, different signs and symptoms, etc.) that may result from aspecific genotype",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutation",
"      </td>",
"      <td>",
"       A change in the sequence of DNA that results in a phenotypic change; a mutation may be beneficial, neutral or harmful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Polymorphism",
"      </td>",
"      <td>",
"       A variation in DNA sequence that occurs in greater than 1 percent of the population",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Presymptomatic",
"      </td>",
"      <td>",
"       Term used in predictive genetic testing to identify persons at increased risk for genetic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Predispositional",
"      </td>",
"      <td>",
"       Term used in predictive genetic testing; refers to detecting a genotype with less than 100 percent penetrance in an asymptomatic individual - ie, the person may or may not develop the condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Types of chromosomes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       Autosomal chromosomes",
"      </td>",
"      <td>",
"       22 paired sets that are not sex chromosomes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Allele",
"      </td>",
"      <td>",
"       Each of the pair of genes on the homologous chromosomes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Homozygous",
"      </td>",
"      <td>",
"       When both of the paired alleles have the mutation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Heterozygous",
"      </td>",
"      <td>",
"       When the mutation occurs on only one of the allele pairs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Compound heterozygote",
"      </td>",
"      <td>",
"       Genotype formed by each allele having a different mutation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Sex-linked chromosome",
"      </td>",
"      <td>",
"       The X and Y chromosomes - XX in females, XY in males",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Modes of inheritance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Multifactorial",
"      </td>",
"      <td>",
"       A constellation of genetic and environmental factors that interact to produce a specific condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       Mendelian inheritance",
"      </td>",
"      <td>",
"       Autosomal dominant and recessive inheritance, and x-linked inheritance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Autosomal dominant inheritance",
"      </td>",
"      <td>",
"       When a disorder can result if one of a specific pair of genes has a mutation. Child of an affected individual has a 50 percent chance of inheriting the gene involved.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Autosomal recessive inheritance",
"      </td>",
"      <td>",
"       When a disorder can result only if both genes in a specific pair have a mutation. Child of an affected individual has a 25 percent chance of inheriting the gene involved.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       X-linked inheritance",
"      </td>",
"      <td>",
"       Mutation exists on X-chromosome: Most x-linked conditions are recessive - two copies of a specific gene on the paired X chromosome must be abnormal for a female to be affected.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       Non-Mendelian inheritance",
"      </td>",
"      <td>",
"       Pattern of inheritance that is not autosomal dominant, autosomal recessive or x-linked",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Polygenic",
"      </td>",
"      <td>",
"       When more than one gene is involved in producing a condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Mitochondrial",
"      </td>",
"      <td>",
"       Condition arising from a mutation in the DNA of the mitochondria, inherited from the mother only",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Types of genetic testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diagnostic genetic testing",
"      </td>",
"      <td>",
"       Assessment DNA sequence or structure for defined genetic risk factors for the purpose of supporting a specific disease diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carrier screening",
"      </td>",
"      <td>",
"       Assessment DNA sequence or structure for specific disease causing alleles in at risk populations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prenatal testing",
"      </td>",
"      <td>",
"       Assessment of fetal DNA sequence or structure for specific disease-causing alleles or karyotypes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preimplantation testing",
"      </td>",
"      <td>",
"       Assessment of sequence or structure of blastocyst derived DNA with the purpose of selecting embryos for implantation that are free of pathogenic genotypes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Newborn screening",
"      </td>",
"      <td>",
"       A variety of genetic and metabolic tests performed in the newborn period for the purposes of early (ie, preclinical) identification of children with disease-causing genotypes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24685=[""].join("\n");
var outline_f24_6_24685=null;
var title_f24_6_24686="Sleep efficiency elderly";
var content_f24_6_24686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sleep efficiency in subjects with normal sleep and age-related insomnia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 335px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <span class=\"red\">",
"     Red:",
"    </span>",
"    subjects with normal sleep.",
"    <br>",
"     <span class=\"blue\">",
"      Blue:",
"     </span>",
"     subjects with age-related insomnia.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia.&nbsp;J Clin Endocrinol Metab 2001; 86:4727.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24686=[""].join("\n");
var outline_f24_6_24686=null;
var title_f24_6_24687="Avulsion fracture fifth metatarsal tuberosity";
var content_f24_6_24687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Avulsion fracture of the fifth metatarsal tuberosity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fracture of the fifth metatarsal tuberosity (black arrow)&nbsp;is seen on this plain radiograph. Although this view&nbsp;suggests the fracture fragment is displaced, additional views are needed to make this determination definitively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_6_24687=[""].join("\n");
var outline_f24_6_24687=null;
